var title_f28_49_29456="Post traumatic arthritis";
var content_f28_49_29456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Post traumatic arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient sustained an elbow fracture in the past. Osteoarthritis is now manifest by severe narrowing of the joint space, sclerosis (black arrow), and osteophytes (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29456=[""].join("\n");
var outline_f28_49_29456=null;
var title_f28_49_29457="EB virus vulva";
var content_f28_49_29457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar Epstein-Barr virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 240px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29457=[""].join("\n");
var outline_f28_49_29457=null;
var title_f28_49_29458="Fluorescein and benoxinate: Drug information";
var content_f28_49_29458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluorescein and benoxinate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5095228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      EyeFlur;",
"     </li>",
"     <li>",
"      Fluress&reg;;",
"     </li>",
"     <li>",
"      Flurox&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5095232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anesthetic, Topical;",
"     </li>",
"     <li>",
"      Diagnostic Agent;",
"     </li>",
"     <li>",
"      Ophthalmic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5095251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Removal of foreign bodies, sutures, or tonometry:",
"     </b>",
"     Ophthalmic: Instill 1 or 2 drops (single instillations) into each eye before operating",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Deep ophthalmic anesthesia:",
"     </b>",
"     Ophthalmic: Instill 2 drops into each eye every 90 seconds up to 3 doses",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5095254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     EyeFlur, Fluress&reg;, Flurox&trade;: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5095230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5095252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of an eye patch is recommended following application.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5095233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For use in ophthalmic procedures when a topical disclosing agent is needed along with an anesthetic",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5095242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Contact dermatitis, drying/fissuring of fingertips",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Conjunctival redness, burning, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hyperallergic corneal reaction has also been reported and includes acute, intense and diffuse epithelial keratitis; gray ground glass appearance; sloughing or large areas of necrotic epithelium; corneal filaments; iritis with descemetitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5095237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluorescein, benoxinate, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5095238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS stimulation/depression: Rarely, CNS stimulation followed by depression may occur following topical application of local anesthetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergies/asthma: Use with caution in patients with history of hypersensitivity, allergies, or asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For ophthalmic use only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged use: Delayed wound healing and/or permanent corneal opacification with vision loss may occur with prolonged use (not recommended).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5095234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5095235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Refer to Fluorescein monograph.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5095236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Fluorescein monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Altafluor Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-0.4% (5 mL): $11.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fluorescein-Benoxinate Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-0.4% (5 mL): $7.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fluress Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-0.4% (5 mL): $11.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Flurox Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-0.4% (5 mL): $15.48",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5095247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluorescein is a diagnostic dye; benoxinate is a rapid acting anesthetic with short duration.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8913 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29458=[""].join("\n");
var outline_f28_49_29458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095228\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095232\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095251\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896226\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896227\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095254\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095230\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095252\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095233\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095242\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095237\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095238\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095234\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095235\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095236\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324142\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5095247\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8913\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8913|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_49_29459="Subarachnoid hemorrhage PI";
var content_f28_49_29459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Subarachnoid hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 567px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A subarachnoid hemorrhage is a type of stroke. It causes bleeding around the brain. The bleeding happens between the brain and the thin layer of tissue that covers it.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29459=[""].join("\n");
var outline_f28_49_29459=null;
var title_f28_49_29460="Ranolazine: Patient drug information";
var content_f28_49_29460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ranolazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/2/34854?source=see_link\">",
"     see \"Ranolazine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2528121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ranexa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ranolazine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11572 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29460=[""].join("\n");
var outline_f28_49_29460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528121\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013076\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013078\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013077\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013082\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013083\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013085\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013080\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013081\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013086\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013087\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/2/34854?source=related_link\">",
"      Ranolazine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_49_29461="Gadofosveset: Drug information";
var content_f28_49_29461=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gadofosveset: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/24/36227?source=see_link\">",
"    see \"Gadofosveset: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10117337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10117338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ablavar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5219405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent;",
"     </li>",
"     <li>",
"      Gadolinium-Containing Contrast Agent;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Nonionic, Low Osmolality);",
"     </li>",
"     <li>",
"      Radiological/Contrast Media, Paramagnetic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5219558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     MRA: I.V.: 0.03 mmol/kg (0.12 mL/kg )",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5219559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5219560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment is not recommended; however, use with caution. Risk for NSF development increases as renal function decreases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo, 2007). Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first to third hemodialysis sessions, respectively (Kuo, 2007; Okada, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe, 1998; Kuo, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Limited data suggest pharmacokinetics of gadofosveset in patients with hepatic disease do not differ substantially.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5219567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ablavar&reg;: 0.25 mmol/mL (10 mL, 15 mL)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vasovist&reg;: 0.25 mmoL/mL (10 mL, 15 mL, 20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5219403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5219562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as an intravenous bolus injection over a period up to 30 seconds through a dedicated I.V. line separate from other medications. Flush line with 25-30 mL NS after administration to ensure complete injection of medium. Imaging should be completed within 1 hour of injection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5219407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium used in magnetic resonance angiography (MRA) to evaluate or better define aortoiliac occlusive disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5219400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vasovist [Hungary, Turkey] may be confused with Gadavist brand name for gadobutrol [U.S.]; Gadovist brand name for gadobutrol [Canada and multiple international markets]; Magnevist brand name for gadopentetate dimeglumine [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5219516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Vasodilatation (3%), hypertension (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4%), dizziness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (4%), taste disturbance (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site: Bruising (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Burning sensation (2%), cold feeling (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1%, postmarketing, and/or case reports (Limited to important or life-threatening): Acute renal failure, anaphylaxis, anaphylactoid reaction, nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (NSF/NFD), QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5219412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gadofosveset, any gadolinium-based contrast agent, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5219413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Delayed reactions may also occur (within several hours of administration). Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrogenic systemic fibrosis:",
"     <b>",
"      [U.S. Boxed Warning]: Gadolinium-based contrast agent (GBCA) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ).",
"     </b>",
"     The risk appears lower in patients with moderate, chronic renal disease (GFR 30-59 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) and little, if any, in patients with mild, chronic renal disease (GFR 60-89 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ). NSF, a potentially fatal disease, affects the skin, muscle, and internal organs and can occur days to months after exposure. All patients should be screened for renal dysfunction prior to administration; estimate GFR in patients at risk for chronic renal disease (diabetes, hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration is preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation: Rare cases of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation have been observed with gadofosveset use. Data from pooled safety studies have demonstrated that the administration of gadofosveset resulted in minimal changes to the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval as compared to placebo (means of 2.8 msec and 3.2 msec respectively). Consider baseline and follow up ECG in patients at increased risk of arrhythmias due to QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (eg, underlying cardiac disease, concurrent medications). Patients should be monitored for at least 1 hour after the administration of gadofosveset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoalbuminemia: Elimination of gadofosveset may be quicker in patients with decreased levels of serum albumin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency following use of other gadolinium agents, generally within 48 hours following administration. Dosage reductions may be necessary. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell anemia: In",
"     <i>",
"      in vitro",
"     </i>",
"     studies, deoxygenated sickle erythrocytes align perpendicular to a magnetic field; the enhancement of magnetic moment by contrast agents may potentiate this alignment possibly resulting in vaso-occlusive complications",
"     <i>",
"      in vivo",
"     </i>",
"     . Use in patients with sickle cell anemia or other hemoglobinopathies has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Contrast agents: Safety and efficacy have not been studied for the use of gadofosveset in conjunction with other contrast agents (eg, iodine-containing, gadolinium based). Use caution in patients who have received iodine-containing agents within 72 hours or other gadolinium-based agents within 24 hours prior to gadofosveset administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5219542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10117339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5219408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gadolinium-based contrast agents are excreted in breast milk in small amounts and oral absorption is poor; information specific to gadofosveset is not available. Although some sources state breast-feeding may be continued, the manufacturer does not recommend use in breast-feeding women unless diagnostic imaging is essential and cannot be obtained by noncontrast MRA. Contrast media may temporarily alter the taste of breast milk (Tremblay, 2012; Webb, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5219410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5219411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low amounts of gadolinium (0.01% to 0.04%) are excreted into breast milk. The manufacturer does not recommend use in breast-feeding women unless diagnostic imaging is essential and cannot be obtained by noncontrast MRA.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ablavar Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     244 mg/mL (10 mL): $145.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5219565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline ECG if risk factors for QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation/torsade de pointes; baseline electrolytes (including potassium, calcium and magnesium); screen for renal impairment (all patients); baseline renal function in patients at risk of NSF and follow-up evaluation with renal dysfunction; signs of hypersensitivity (during and for several hours after procedure); short- and long-term monitoring of signs and symptoms of NSF/NFD (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye); patients should be monitored for at least 1 hour after administration of gadofosveset.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Vasovist (AT, CH, CZ, DE, DK, EE, GR, HN, IE, NL, NO, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5219546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Gadolinium-based contrast agents cross the placenta in humans. Gadolinium-based agents should not routinely be administered to pregnant women (Expert Panel on MR Safety, 2013; Wang, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5219548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: ~15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 148 &plusmn; 16 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 80% to 87% (predominantly to albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~16 hours; moderate renal impairment: 49 hours; severe renal impairment: 70 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (84% as unchanged drug); feces (~5%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Caravan P, Cloutier NJ, Greenfield MT, et al, &ldquo;The Interaction of MS-325 With Human Serum Albumin and Its Effect on Proton Relaxation Rates,&rdquo;",
"      <i>",
"       J Am Chem Soc",
"      </i>",
"      , 2002, 124(12): 3152-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/11902904/pubmed\" id=\"11902904\" target=\"_blank\">",
"        11902904",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel on MR Safety, \"ACR Guidance Document on MR Safe Practices: 2013,\"",
"      <i>",
"       J Magn Reson Imaging",
"      </i>",
"      , 2013, 37(3):501-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/23345200/pubmed\" id=\"23345200\" target=\"_blank\">",
"        23345200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joffe P, Thomsen HS, and Meusel M, \"Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis,\"",
"      <i>",
"       Acad Radiol",
"      </i>",
"      , 1998, 5(7):491-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/9653466/pubmed\" id=\"9653466\" target=\"_blank\">",
"        9653466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuo PH, Kanal E, Abu-Alfa AK, et al, \"Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis,\"",
"      <i>",
"       Radiology",
"      </i>",
"      , 2007, 242(3):647-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/17213364/pubmed\" id=\"17213364\" target=\"_blank\">",
"        17213364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauffer RB, Parmelee DJ, Dunham SU, et al, &ldquo;MS-325: Albumin-Targeted Contrast Agent for MR Angiography,&rdquo;",
"      <i>",
"       Radiology",
"      </i>",
"      , 1998, 207(2): 529-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/9577506/pubmed\" id=\"9577506\" target=\"_blank\">",
"        9577506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Okada S, Katagiri K, Kumazaki T, et al, &ldquo;Safety of Gadolinium Contrast Agent in Hemodialysis Patients,&rdquo;",
"      <i>",
"       Acta Radiol",
"      </i>",
"      , 2001, 42(3):339-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/11350296/pubmed\" id=\"11350296\" target=\"_blank\">",
"        11350296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perreault P, Edelman MA, Baum RA, et al, &ldquo;MR Angiography with Gadofosveset Trisodium for Peripheral Vascular Disease: Phase II Trial,&rdquo;",
"      <i>",
"       Radiology",
"      </i>",
"      , 2003, 229(3):811-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/14593194/pubmed\" id=\"14593194\" target=\"_blank\">",
"        14593194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shamsi K, Yucel EK, and Chamberlin P, &ldquo;A Summary of Safety of Gadofosveset (MS-325) at 0.03 mmol/kg Body Weight Dose,&rdquo;",
"      <i>",
"       Invest Radiol",
"      </i>",
"      , 2006, 41(11): 822-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/17035873/pubmed\" id=\"17035873\" target=\"_blank\">",
"        17035873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tremblay E, Th&eacute;rasse E, Thomassin-Naggara I, et al, \"Quality Initiatives: Guidelines for Use of Medical Imaging During Pregnancy and Lactation,\"",
"      <i>",
"       Radiographics",
"      </i>",
"      , 2012, 32(3):897-911.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/22403117/pubmed\" id=\"22403117\" target=\"_blank\">",
"        22403117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang PI, Chong ST, Kielar AZ, et al, \"Imaging of Pregnant and Lactating Patients: Part 1, Evidence-Based Review and Recommendations,\"",
"      <i>",
"       AJR Am J Roentgenol",
"      </i>",
"      , 2012, 198(4):778-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/22451541/pubmed\" id=\"22451541\" target=\"_blank\">",
"        22451541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Webb JA, Thomsen HS, and Morcos SK, \"The Use of Iodinated and Gadolinium Contrast Media During Pregnancy and Lactation,\"",
"      <i>",
"       Eur Radiol",
"      </i>",
"      , 2005, 15(6):1234-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29461/abstract-text/15609057/pubmed\" id=\"15609057\" target=\"_blank\">",
"        15609057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8833 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29461=[""].join("\n");
var outline_f28_49_29461=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117337\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117338\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219405\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219558\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219559\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219560\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896299\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219567\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950124\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219403\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219562\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219407\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219400\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219516\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219412\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219413\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299378\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219542\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117339\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219408\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219410\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219411\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324146\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219565\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038898\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219546\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5219548\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8833\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8833|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/24/36227?source=related_link\">",
"      Gadofosveset: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_49_29462="Calcipotriol (calcipotriene) and betamethasone: Drug information";
var content_f28_49_29462=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcipotriol (calcipotriene) and betamethasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/17/22804?source=see_link\">",
"    see \"Calcipotriol (calcipotriene) and betamethasone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2524976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Taclonex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dovobet&reg;;",
"     </li>",
"     <li>",
"      Xamiol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical;",
"     </li>",
"     <li>",
"      Vitamin D Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F140723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Plaque psoriasis:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel (Xamiol&reg; [CAN]): Apply to affected area of scalp once daily for up to 4 weeks (maximum recommended dose: 15 g daily or 100 g weekly). Application to &gt;30% of body surface area is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Apply to affected area of skin once daily for up to 4 weeks (maximum recommended dose: 100 g weekly). Application to &gt;30% of body surface area is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension: Apply to affected area of skin or scalp once daily for up to 8 weeks (maximum recommended dose: 100 g weekly)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F140724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F140725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied in severe renal impairment).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2525021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied in severe hepatic impairment).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Taclonex&reg;: Calcipotriene 0.005% and betamethasone dipropionate 0.064% (60 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Taclonex&reg;: Calcipotriene 0.005% and betamethasone dipropionate 0.064% (60 mL) [contains castor oil]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10074488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Xamiol&reg;: Calcipotriol 50 mcg/g and betamethasone dipropionate 0.5 mg/g (30 g, 60 g, 2 x 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dovobet&reg;: Calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (30 g, 60 g,  120 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2763809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2525022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash hands before and after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel (Xamiol&reg; [CAN]): Shake well before use. Avoid use of occlusive dressings over treated areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Rub into affected area gently and completely. Do not apply to face, axillae, or groin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension: Shake well before use. Do not apply to face, axillae, or groin. If applying to the scalp, do not apply within 12 hours of chemical hair treatment. Do not wash hair directly after use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F140714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of plaque psoriasis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F140730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of corticosteroid-responsive dermatoses",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Dermatologic: Pruritus (4%), erythema (2%), irritation (1%), scaly rash (1%), burning sensation (&le;1%), folliculitis (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acne, contact dermatitis, dermatitis, dry skin, eye irritation, facial edema, HPA axis suppression, hypercalcemia, hypercalciuria, otitis externa, papular rash, psoriasis exacerbation, pustular psoriasis, pustular rash, rash, rebound effect, skin atrophy, skin hyper-/hypopigmentation, skin pain, telangiectasia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F140716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the FDA-approved labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling (not in U.S. labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hypersensitivity to calcipotriene, betamethasone, or any component of the formulation; viral (herpes simplex, varicella, vaccinia), fungal or bacterial infection of the skin; tuberculosis of the skin; syphilitic skin infections; ophthalmic use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gel: Disorders of calcium metabolism; acne rosacea, acne vulgaris, atrophic skin, fragility of skin veins, ichthyosis, perioral dermatitis, parasitic infections, psoriasis (erythrodermic, exfoliative, guttate, and pustular), rosacea, severe hepatic disorders, severe renal insufficiency, skin ulcers and wounds, striae atrophicae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ointment: Eruptions following vaccinations",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F140707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur; it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercalcemia/hypercalciuria: May cause transient increases in serum and urinary calcium (reversible); if hypercalcemia or hypercalciuria occurs, discontinue treatment until levels return to normal. Use with caution in patients with or history of disorders of calcium metabolism; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Safety and efficacy have not been established in patients with erythrodermic, exfoliative, or pustular psoriasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin infections: Use appropriate antibacterial or antifungal agents to treat concomitant skin infections; if infection persists, discontinue use of calcipotriene and betamethasone until infection has resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may be at higher risk of systemic side effects due to a greater skin surface area:body weight ratio. Children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do not use on the face, axillae, groin, or in the presence of pre-existing skin atrophy at the treatment site. Ointment is not for oral, ophthalmic, or intravaginal use. Avoid exposure of suspension to the eyes; irritation may occur. Avoid excessive exposure of treated skin to sunlight (natural or artificial).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2524977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2524978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this topical combination. There are no adequate and well-controlled studies in pregnant women. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F140726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F140717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Taclonex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005-0.064% (60 g): $730.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Taclonex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005-0.064% (60 g): $700.44",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10074486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline serum calcium levels and then periodically during treatment in patients at risk for hypercalcemia",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F140718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Daivobet (AU, BG, BR, CH, CL, CO, CR, CZ, DE, DK, DO, EC, EE, FI, FR, GT, HK, HN, ID, KP, MY, NO, NZ, PA, PH, PT, SE, SG, SV, TH, TW);",
"     </li>",
"     <li>",
"      Dovobet (BE, GB, IE);",
"     </li>",
"     <li>",
"      Xamiol (HK, IL, KP, MY, PH, SG, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F140706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcipotriene is a vitamin D derivative and betamethasone dipropionate ointment is a high-potency corticosteroid.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10074484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/49/29462/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9406 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-109.224.62.197-C12E3FDE9F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29462=[""].join("\n");
var outline_f28_49_29462=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140722\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140733\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140723\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140724\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140725\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525021\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140713\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074488\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2763809\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525022\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140714\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140730\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140731\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140716\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140707\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298927\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218753\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524977\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524978\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140726\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140717\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422202\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074486\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140718\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140706\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074484\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9406\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9406|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/17/22804?source=related_link\">",
"      Calcipotriol (calcipotriene) and betamethasone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_49_29463="HRCT NTM lung disease";
var content_f28_49_29463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    High resolution computed tomography of nontuberculous mycobacterial pulmonary disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    17-year-old patient with cystic fibrosis and sputum culture positive for",
"    <em>",
"     Mycobacterium avium",
"    </em>",
"    -",
"    <em>",
"     intracellulare",
"    </em>",
"    in association with declining pulmonary function and weight loss. Note the multiple bilateral nodular opacities distributed in a bronchovascular pattern (black arrows). Moderate bronchiectasis is demonstrated by dilated airways and bronchial wall thickening (yellow arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy Sheldon L Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29463=[""].join("\n");
var outline_f28_49_29463=null;
var title_f28_49_29464="Intracranial subdural hematoma in children: Clinical features, evaluation, and management";
var content_f28_49_29464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intracranial subdural hematoma in children: Clinical features, evaluation, and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/49/29464/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29464/contributors\">",
"     Mark R Proctor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/49/29464/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29464/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/49/29464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29464/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/49/29464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural hematoma (SDH) forms when there is hemorrhage into the potential space between the dura and the arachnoid membranes. SDH in children differs significantly from SDH in adults because abusive head injury is a common etiology, especially in pediatric patients &lt;2 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast to epidural hematoma (EDH), indications for operative management of SDH are less clear, and surgery is less likely to prevent morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review will discuss the clinical features, evaluation, and management of subdural hematoma in children. The epidemiology, anatomy, and pathophysiology of SDH in children and SDH in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21575?source=see_link\">",
"     \"Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=see_link\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43767?source=see_link\">",
"     \"Subdural hematoma in adults: Prognosis and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview summarizes the important clinical features and initial management of SDH in children (",
"    <a class=\"graphic graphic_table graphicRef82616 \" href=\"UTD.htm?25/3/25660\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the abused infant or young child, SDH is frequently discovered after physical examination and imaging. The history usually does not provide a plausible mechanism for the severity of injury and may be misleading. Frequently no mention of trauma of any kind is given. Common presenting complaints include altered mental status, seizures, apnea, breathing difficulty, or sudden cardiopulmonary arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historical features may suggest an increased risk of SDH in patients with unintentional injury, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk trauma mechanism such as motor vehicle collision or fall from a significant height (&gt;3 times patient height) (",
"      <a class=\"graphic graphic_table graphicRef57293 \" href=\"UTD.htm?0/42/684\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Seizure, confusion, headache, vomiting, or loss of consciousness",
"     </li>",
"     <li>",
"      Past medical history of predisposing illness, including (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21575?source=see_link&amp;anchor=H19#H19\">",
"       \"Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology\", section on 'Minor head injury'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bleeding disorder (hemophilia, thrombocytopenia)",
"     </li>",
"     <li>",
"      Cerebral atrophy or treated hydrocephalus",
"     </li>",
"     <li>",
"      Arachnoid cyst",
"     </li>",
"     <li>",
"      Osteogenesis imperfecta",
"     </li>",
"     <li>",
"      Glutaric aciduria, type I",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the strong association between SDH and child abuse in infants and toddlers &le;2 years of age and because a history of head trauma is usually lacking, the clinician must maintain a high index of suspicion during physical examination of any child in this age group.",
"   </p>",
"   <p>",
"    In children with unintentional head injury, SDH can manifest as an alteration of mental status or focal neurologic deficit. Other findings might include fullness of the fontanelle or a jump in head growth.",
"   </p>",
"   <p>",
"    Up to 8 percent of neonates may develop a small SDH during labor and delivery but usually remain asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21575?source=see_link&amp;anchor=H2#H2\">",
"     \"Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Abusive head injury (shaken baby syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abused infants with SDH are typically &lt;2 years of age. External evidence of head injury, such as scalp hematoma, may be absent. These children demonstrate nonspecific clinical signs of brain injury, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      Bulging anterior fontanelle",
"     </li>",
"     <li>",
"      Increased head circumference when compared with growth chart or prior measurements",
"     </li>",
"     <li>",
"      Pallor with anemia",
"     </li>",
"     <li>",
"      Lethargy, coma, or seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Large amounts of intracranial blood can accumulate prior to changes in the neurologic examination and may cause fever or hemorrhagic shock, particularly in infants with open fontanelles and cranial sutures.",
"   </p>",
"   <p>",
"    Bradycardia and pupillary changes are late findings often associated with rapid neurologic deterioration and poor outcomes despite rapid intervention. Because of delay in seeking medical attention, abused children with SDH may also present in cardiopulmonary arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H4#H4\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retinal hemorrhages, skull and skeletal fractures commonly accompany SDH in children with abusive head injury (shaken baby syndrome) and indicate major traumatic force that usually does not match the history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other signs of physical abuse that should be sought include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unusual bruises (eg, loop mark, bite mark) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"       \"Physical abuse in children: Diagnostic evaluation and management\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Bruises in various stages of healing",
"     </li>",
"     <li>",
"      Cigarette burns",
"     </li>",
"     <li>",
"      Injuries to the genitalia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When abusive head injury is suspected, involvement of an experienced child protection team is crucial, and in many parts of the world (including the US, UK, and Australia), reporting to a governmental agency is mandatory. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Unintentional head injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial bleeding should be suspected if there is a witnessed deterioration in neurologic status after an unintentional head injury. Depending upon the severity of traumatic injury, the child may present with a scalp hematoma and varying degrees of impaired consciousness and Glasgow Coma Score (GCS) (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 3",
"    </a>",
"    ). Often a small SDH is found by computed tomography (CT) of the head in patients who are neurologically intact. In these children, common symptoms include headache, vomiting, or irritability.",
"   </p>",
"   <p>",
"    Infants with mild head injury and SDH should undergo evaluation for predisposing factors including bleeding tendency, osteogenesis imperfecta, and glutaric aciduria type 1 although abusive head injury is still the most likely etiology in these children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link&amp;anchor=H33#H33\">",
"     \"Organic acidemias\", section on 'Glutaric aciduria type 1'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other children will present in coma from large hematomas, possibly requiring urgent surgical evacuation. Lateralizing neurologic signs (eg, anisocoria, hemiparesis, hemiplegia) arise from compression of the third cranial nerve and brainstem. These are indicators of progression to cerebral uncal herniation. The side of the dilated pupil matches the side of the hematoma in roughly 90 percent of cases. The constellation of systemic hypertension, bradycardia, and respiratory depression (Cushing triad) is another late sign, and may be a preterminal event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRIMARY EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview summarizes the important clinical features and initial management of SDH (",
"    <a class=\"graphic graphic_table graphicRef82616 \" href=\"UTD.htm?25/3/25660\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initial assessment and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The order of priority in the initial assessment and treatment of the injured child with possible SDH is the same as for any trauma patient (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A - Airway maintenance with cervical spine protection",
"     </li>",
"     <li>",
"      B - Breathing and ventilation",
"     </li>",
"     <li>",
"      C - Circulation with hemorrhage control",
"     </li>",
"     <li>",
"      D - Disability (evaluation of neurologic status)",
"     </li>",
"     <li>",
"      E - Exposure (complete",
"      <span class=\"nowrap\">",
"       visualization)/environmental",
"      </span>",
"      control (prevention of hypothermia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A rapid neurologic examination should focus on mental status using an age-appropriate GCS (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 3",
"    </a>",
"    ), pupillary findings, cranial nerves, and motor function. Patients with concerns for significant intracranial injury or increased ICP must be managed appropriately to reduce the likelihood of secondary brain injury from hypoxia, ischemia, and cerebral edema.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician should provide supplemental oxygen to keep saturation &gt;95 percent.",
"     </li>",
"     <li>",
"      Cervical spine immobilization should be maintained throughout emergent patient care in all patients. Those patients with altered mental status should continue to be immobilized even if radiographic studies show no bony abnormality until the patient is awake and can be fully assessed.",
"     </li>",
"     <li>",
"      Head injured patients with compromised airway, inadequate breathing, or severe neurologic findings (GCS &le;8, pupillary abnormalities, neurologic deficit, or rapidly declining mental status) require early rapid sequence endotracheal intubation using measures to prevent increased ICP (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Aggressive hyperventilation (PaCO2 &lt;30 mmHg) may cause cerebral ischemia as the result of decreased cerebral blood flow. Consequently, PaCO2 should be maintained between 35 and 40 mmHg unless there are signs of impending herniation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link&amp;anchor=H16#H16\">",
"       \"Initial approach to severe traumatic brain injury in children\", section on 'Rapid sequence intubation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H15#H15\">",
"       \"Elevated intracranial pressure in children\", section on 'Breathing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with hypotension require rapid fluid resuscitation to maintain cerebral perfusion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H12#H12\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Circulation'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neurosurgical consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any pediatric trauma patient with a GCS &le;12 (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 3",
"    </a>",
"    ) warrants emergent consultation and evaluation by a neurosurgeon. Children with a GCS &le;8 should undergo intracranial ICP monitoring. Specific therapies targeted at increased ICP are ideally employed in consultation with a neurosurgeon and include sedation and osmotic therapy using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    or hypertonic saline infusion. These treatments are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;To assess for anemia, bleeding tendency, and prepare for possible surgery, we recommend the following blood studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with platelets",
"     </li>",
"     <li>",
"      Prothrombin time (PT)",
"     </li>",
"     <li>",
"      Partial thromboplastin time (PTT)",
"     </li>",
"     <li>",
"      International normalized ratio (INR)",
"     </li>",
"     <li>",
"      Bleeding time (if available)",
"     </li>",
"     <li>",
"      Type and cross",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies (eg, AST, ALT, and urinalysis) may be indicated in multiple trauma patients and suspected victims of abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial approach to severe traumatic brain injury in children\", section on 'Laboratory studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H6#H6\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the risk of herniation, lumbar puncture is contraindicated in cases where a space-occupying lesion such as SDH is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;On CT, a SDH typically appears concave as it spreads across the brain surface unrestricted by cranial sutures, whereas an EDH is lenticular and does not cross suture lines (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74235 \" href=\"UTD.htm?36/22/37231\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79566 \" href=\"UTD.htm?25/52/26432\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link&amp;anchor=H13#H13\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\", section on 'Radiographic imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Abusive head injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging is an essential component of the evaluation of children with suspected inflicted head injury. In addition to establishing the diagnosis, imaging may provide documentation of the extent and timing of injuries. Because it is rapidly available and quick, unenhanced computed tomography (CT) of the head is the initial study of choice (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78781 \" href=\"UTD.htm?3/1/3094\">",
"     image 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H10#H10\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link\">",
"     \"Approach to neuroimaging in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Homogeneous hyperdense subdural hematoma is more frequent in cases of unintentional head trauma.",
"     </li>",
"     <li>",
"      Mixed-density subdural hematoma may be seen in cases of nonaccidental head injury due to repetitive injuries, but may be observed within 48 hours of unintentional head trauma.",
"     </li>",
"     <li>",
"      Interhemispheric hematomas and hematomas in multiple sites are seen almost exclusively in inflicted injury [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending on the degree of brain injury and size of hematoma, there may be associated uncal, subfalcine, or transtentorial herniation, as well as other signs of ischemia or hypoxia such as loss of grey-white distinctions in the brain on CT. In addition, EDH, cerebral contusion, and subarachnoid hemorrhage may be present.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) is preferred for infants who are stable but require neuroimaging because of other injuries indicating physical abuse found on clinical examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skeletal survey. In addition, MRI can be done in follow-up for patients with abnormal CT findings (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78781 \" href=\"UTD.htm?3/1/3094\">",
"     image 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Unintentional injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any head injury, a patient who presents with altered mental status after a significant trauma warrants emergent unenhanced head CT. Although it offers less diagnostic accuracy than MRI, it detects SDH well enough to guide management and is more rapidly obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For clinically stable children with clear signs of extraaxial hemorrhage (ie, bleeding outside of the brain parenchyma) on CT, but for whom the space (epidural, subdural, or subarachnoid) in which the hemorrhage has occurred is less clear, it is often prudent to obtain further imaging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with an open anterior fontanelle, a bedside ultrasound with duplex Doppler may rapidly distinguish between subdural and subarachnoid hemorrhage by detecting the course of blood vessels through the extraaxial space.",
"     </li>",
"     <li>",
"      MRI, when the clinical situation allows, is the preferred modality because it accurately identifies the space involved and demarcates the associated brain injury, such as stroke or contusion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61410 \" href=\"UTD.htm?9/35/9782\">",
"       image 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Making the distinction between enlarged subdural or subarachnoid space radiographically is important because the underlying cause can be significantly different. Subdural blood implies a higher likelihood of significant traumatic head injury as the etiology. Enlarged subarachnoid spaces may be normal variants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Child protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a SDH in a child with no plausible mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the medical care team should ensure that fundoscopic examination by an ophthalmologist to assess for retinal hemorrhages and skeletal survey occur once the patient's clinical status is stabilized. The safety of other children in the home must be ensured by local Child Protective Services. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DEFINITIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with acute SDH, rapid evaluation and care by a neurosurgeon are key to optimal outcomes. If there is no neurosurgical coverage at the admitting hospital, the child must be resuscitated and promptly transferred to an appropriate institution. A rapid overview summarizes the important clinical features and initial management of SDH in children (",
"    <a class=\"graphic graphic_table graphicRef82616 \" href=\"UTD.htm?25/3/25660\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Operative decision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to perform surgery on children with SDH is based upon physical findings and results of head CT. No clear criteria for operative care exist and no controlled studies of operative approach in children have been performed. Due to the flexibility of the pediatric skull, the indications for surgery might occasionally differ from that of adults, but must be decided on a case by case basis by a neurosurgeon with pediatric expertise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43767?source=see_link&amp;anchor=H8#H8\">",
"     \"Subdural hematoma in adults: Prognosis and management\", section on 'Deciding who needs surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relative to EDH, the clinical presentation and radiographic findings in SDH are much more varied, and the time since injury ranges from hours to weeks. Factors for deliberation include the clinical presentation, the size of the hematoma, and the appearance of the underlying brain injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases, children with acute, unilateral SDH, neurologic impairment, and midline shift on unenhanced head CT should undergo surgical evacuation. Depending on the size and location of the SDH, the timing (acute or chronic), and the presence of other brain abnormality on head CT, immediate surgery is not likely to improve outcome in some children. Therefore, some children with severe brain injury may not be surgical candidates despite the presence of subdural hematoma. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Nonoperative management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Although decompressive craniectomy has been used as a tool in the management of the refractory ICP in children with inflicted head injury, its use is not routine [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This measured approach to operative care in children with SDH contrasts with the urgent need to operate on every child with significant EDH and neurologic compromise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link&amp;anchor=H18#H18\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\", section on 'Operative treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Temporizing procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural taps can be performed in patients with acute signs of life-threatening increased ICP caused by SDH when immediate operative care is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/6\">",
"     6",
"    </a>",
"    ], or can be a primary treatment of the pressure in some infants. In addition, some neurosurgeons perform subdural taps in patients with chronic subdural hematoma or subdural hygroma to facilitate resorption. As many as 42 percent go on to require further taps or another procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], such as a subdural drain placement. For many patients, subdural taps or drain placement are performed as an intermediate step that helps determine the need for a more definitive procedure, such as placement of a subdural peritoneal shunt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;If at all possible, the decision to manage SDH nonoperatively should be made in conjunction with a neurosurgeon who understands the subtleties that would distinguish the more benign lesion from one that is a surgical emergency. In instances where neurosurgery is not physically available to the managing physician and transport to a higher level of care poses risk to the patient, phone consultation and remote review of the head CT by a neurosurgeon may assist in guiding proper patient disposition and care.",
"   </p>",
"   <p>",
"    Frequently children who are comatose with severe brain swelling and infarction are not good candidates for surgical evacuation of a SDH. This situation contrasts sharply with EDH in children, for which urgent surgery is always indicated when significant neurologic compromise is present. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Operative decision'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link&amp;anchor=H18#H18\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\", section on 'Operative treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of children with SDH in whom medical management might be appropriate include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A comatose child with a small SDH and severe cerebral edema.",
"     </li>",
"     <li>",
"      Children with acute bilateral subdural hematoma after inflicted head injury. Surgical evacuation in these patients can lower ICP and improve cerebral hemodynamics [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/5,9\">",
"       5,9",
"      </a>",
"      ]. Unfortunately, evacuation of the subdural in these cases may not significantly improve outcome, which is ultimately determined by severity of cerebral edema and primary brain injury (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74235 \" href=\"UTD.htm?36/22/37231\">",
"       image 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/7,10,11\">",
"       7,10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children who are minimally symptomatic with a small SDH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children managed nonoperatively should be observed in a facility where experienced pediatric trained personnel can monitor for neurologic changes. Patients with GCS &le;8 should have continuous intracranial monitoring of ICP during observation if the medical situation allows for safe insertion of the monitor. In addition, 24 hour emergency access to head CT and a properly equipped operating room are essential, as deterioration can occur at any time.",
"   </p>",
"   <p>",
"    A repeat head CT should be obtained within 24 hours or sooner if concerning features exist on the initial head CT. In addition, significant clinical deterioration requires emergent repeat head CT. Observational studies in children show that reimaging with a head CT detects an increase in SDH size in up to 14 percent of patients and that 4 percent undergo surgical evacuation or other procedure based on this progression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the risk of marked change in the size of a SDH with neurologic sequelae, even asymptomatic children with a small SDH should generally be admitted to the hospital for observation and possible reimaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Surgical procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;When surgical intervention is required, craniotomy or craniectomy will successfully evacuate the SDH in approximately 80 percent of patients and is used for acute hematomas with or without associated brain swelling. Postoperative infection in up to 17 percent of children has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subdural peritoneal shunt placement is used for chronic SDH that is unresponsive to subdural taps and eliminates the subdural hematoma in most cases [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/7,14\">",
"       7,14",
"      </a>",
"      ]. Subsequent obstruction is seen in up to 14 percent of patients with an infection rate of 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/14\">",
"       14",
"      </a>",
"      ]. Many surgeons choose to remove the subdural shunt after three to six months to avoid long term complications, primarily infection. These shunts are needed in a minority of patients.",
"     </li>",
"     <li>",
"      Burr holes can also be used for drainage of chronic liquefied SDH, but will not work for large clotted hematomas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Timing of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;When surgery is indicated, evidence from observational studies in adults with SDH suggests that surgery within two to four hours after the onset of neurologic deterioration in patients with SDH is associated with a lower mortality than delayed surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43767?source=see_link&amp;anchor=H6#H6\">",
"     \"Subdural hematoma in adults: Prognosis and management\", section on 'Timing of surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After recovery, children with SDH need regular follow-up with possible periodic imaging of the brain to monitor status of the hematoma. Some children may go on to develop a chronic subdural hematoma or subdural hygroma, which at times can be persistent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In infants, following the head circumference is a very effective monitoring tool. Children should be restricted from activities such as contact sports or rough play until all SDH fluid collections have resolved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21575?source=see_link\">",
"     \"Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Victims of inflicted head trauma and their siblings require social placement in a safe family environment and ongoing social and psychological support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link\">",
"     \"Child abuse: Social and medicolegal issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Those patients with neurologic impairment after treatment of SDH should be referred for occupational and physical therapy.",
"   </p>",
"   <p>",
"    Children with iron deficiency anemia from blood loss should receive replacement doses of iron (3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of elemental iron in a single or divided dose for four weeks). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on small observational studies, outcomes following a SDH are best predicted by the neurologic state of the child on presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A neurologically intact child presenting with relatively subtle findings such as increased head circumference",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bulging fontanelle can be predicted to have a reasonably good outcome, even if the hematoma is large.",
"     </li>",
"     <li>",
"      Children presenting with severe alterations in their level of consciousness and significant neurologic symptoms after unintentional head injury typically experience poor outcomes, independent of the size of the SDH, because of coexisting brain injury. In this respect, SDH differs substantially from EDH. Since an EDH often has little underlying brain injury, even a comatose, herniating patient can have an excellent outcome if rapid surgical intervention is achieved. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link&amp;anchor=H25#H25\">",
"       \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\", section on 'Outcome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most victims of inflicted head injury with SDH have a poor outcome. In one series of 33 infants with SDH, most of whom had inflicted head injury, 75 percent died or had profound disability [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29464/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the survivors, inflicted brain injury in children has both short and long term neurologic, behavioral, and cognitive consequences. As with unintentional injury, the best prognostic indicator for neurocognitive recovery after inflicted injury is neurologic condition on presentation. Delayed presentation to a medical facility, low Glasgow coma score at time of presentation, and prolonged duration of coma are all correlated with unfavorable outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H23#H23\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural hematoma (SDH) results from bleeding into the potential space between the dural and the arachnoidal membranes. On CT, a SDH appears concave as it spreads across the brain surface unrestricted by cranial sutures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74235 \" href=\"UTD.htm?36/22/37231\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21575?source=see_link\">",
"     \"Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rapid overview summarizes the important clinical features and initial management of SDH in children (",
"    <a class=\"graphic graphic_table graphicRef82616 \" href=\"UTD.htm?25/3/25660\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflicted head injury (Shaken baby syndrome) is the etiology of SDH in the majority of infants and young children &le;2 years of age. In these patients, the history frequently omits mention of trauma and is often misleading. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children &le;2 years of age with inflicted head injury and SDH demonstrate nonspecific clinical signs of brain injury and may also have associated features of physical abuse (eg, retinal hemorrhage, skull",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      skeletal fractures). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Abusive head injury (shaken baby syndrome)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A history of major head trauma (eg, motor vehicle collision) is usually found in children with SDH caused by unintentional head injury. Predisposing factors (eg, bleeding tendency, cerebral atrophy, arachnoid cyst) may rarely account for the development of SDH in children with a history of minor head injury. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An SDH should be suspected if there is a witnessed deterioration in neurologic status after a head injury. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lateralizing neurologic signs (eg, anisocoria, hemiparesis, hemiplegia) arise from compression of the third cranial nerve and brainstem. These are indicators of progression to cerebral uncal herniation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Unintentional injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Primary evaluation and management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The order of priority in the initial assessment and treatment of the injured child suspected with possible SDH is the same as for any trauma patient (",
"      <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"       figure 1",
"      </a>",
"      ). A rapid neurologic examination should focus on mental status using an age appropriate GCS (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 3",
"      </a>",
"      ), pupillary findings, cranial nerves, and motor function. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial assessment and treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Any child with a GCS &le;12 (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 3",
"      </a>",
"      ) warrants emergent consultation and evaluation by a neurosurgeon. Children with a GCS &le;8 should undergo ICP monitoring. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neurosurgical consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Head CT is the mainstay of diagnostic imaging because of the speed with which it can be obtained and interpreted, and its ability to demarcate in detail the extent of the hemorrhage for surgical planning. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiographic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of a SDH in a child with no plausible mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Child protection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Definitive management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision to perform surgery on children with SDH is based upon physical findings and results of head CT; no clear criteria exist. We recommend that most children with acute SDH, neurologic impairment, and midline shift on unenhanced head CT undergo surgical evacuation (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Subdural taps can be performed in patients with acute signs of life-threatening increased ICP caused by SDH when immediate operative care is not available. Frequently children who are comatose with severe brain swelling and infarct are not good candidates for surgical evacuation of a SDH. This approach contrasts sharply with management of epidural hematoma in children where urgent surgery is always indicated in the presence of significant neurologic compromise. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Operative decision'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Temporizing procedures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Nonoperative management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link&amp;anchor=H18#H18\">",
"       \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\", section on 'Operative treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If at all possible, the decision to manage SDH nonoperatively should be made in conjunction with a neurosurgeon who understands the subtleties that would distinguish the more benign lesion from one that is a surgical emergency. In instances where neurosurgery is not physically available to the managing physician and transport to a higher level of care poses risk to the patient, phone consultation and remote review of the head CT by a neurosurgeon may assist in guiding proper patient disposition and care. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Nonoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with SDH who are initially managed nonoperatively should be admitted to the hospital and observed in a facility where experienced pediatric trained personnel can monitor for neurologic changes. Patients with GCS &le;8 should have continuous monitoring of ICP during observation. In addition, 24 hour emergency access to head CT and a properly equipped operating room are essential, as deterioration can occur at any time. A repeat a head CT at 24 hours or sooner, depending on clinical status, guides further surgical management. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Nonoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The child's neurologic status on presentation best predicts the outcome after a SDH regardless of age or mechanism of injury. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/1\">",
"      Whitby EH, Griffiths PD, Rutter S, et al. Frequency and natural history of subdural haemorrhages in babies and relation to obstetric factors. Lancet 2004; 363:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/2\">",
"      Duffy GP. Lumbar puncture in the presence of raised intracranial pressure. Br Med J 1969; 1:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/3\">",
"      Datta S, Stoodley N, Jayawant S, et al. Neuroradiological aspects of subdural haemorrhages. Arch Dis Child 2005; 90:947.",
"     </a>",
"    </li>",
"    <li>",
"     Proctor MB. Neurosurgical aspects of nonaccidental trauma in children. In: Neurological Surgery Principles and Practice, Loftus B.  (Ed), Lippincott Williams and Wilkins, Philadelphia 2003. p.1065.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/5\">",
"      Cho DY, Wang YC, Chi CS. Decompressive craniotomy for acute shaken/impact baby syndrome. Pediatr Neurosurg 1995; 23:192.",
"     </a>",
"    </li>",
"    <li>",
"     Woodward GA, Carey CM. Subdural hematoma. In: Textbook of Pediatric Emergency Procedures, 2nd, King C, Henretig.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.522.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/7\">",
"      Tolias C, Sgouros S, Walsh AR, Hockley AD. Outcome of surgical treatment for subdural fluid collections in infants. Pediatr Neurosurg 2000; 33:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/8\">",
"      Sauter KL. Percutaneous subdural tapping and subdural peritoneal drainage for the treatment of subdural hematoma. Neurosurg Clin N Am 2000; 11:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/9\">",
"      Meyer PG, Ducrocq S, Rackelbom T, et al. Surgical evacuation of acute subdural hematoma improves cerebral hemodynamics in children: a transcranial Doppler evaluation. Childs Nerv Syst 2005; 21:133.",
"     </a>",
"    </li>",
"    <li>",
"     Proctor MB. Neurosurgical aspects of nonaccidental trauma in children. In: Neurological Surgery and Principles and Practice, Loftus B.  (Ed), Lippincott Williams and Wilkins, Philadelphia 2003. p.1065.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/11\">",
"      Duhaime AC, Gennarelli TA, Thibault LE, et al. The shaken baby syndrome. A clinical, pathological, and biomechanical study. J Neurosurg 1987; 66:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/12\">",
"      Hollingworth W, Vavilala MS, Jarvik JG, et al. The use of repeated head computed tomography in pediatric blunt head trauma: factors predicting new and worsening brain injury. Pediatr Crit Care Med 2007; 8:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/13\">",
"      Durham SR, Liu KC, Selden NR. Utility of serial computed tomography imaging in pediatric patients with head trauma. J Neurosurg 2006; 105:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/14\">",
"      Vinchon M, Noul&eacute; N, Soto-Ares G, Dhellemmes P. Subduroperitoneal drainage for subdural hematomas in infants: results in 244 cases. J Neurosurg 2001; 95:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/15\">",
"      Vinchon M, Defoort-Dhellemmes S, Nzeyimana C, et al. Infantile traumatic subdural hematomas: outcome after five years. Pediatr Neurosurg 2003; 39:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29464/abstract/16\">",
"      Jayawant S, Rawlinson A, Gibbon F, et al. Subdural haemorrhages in infants: population based study. BMJ 1998; 317:1558.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6534 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-016017C18B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29464=[""].join("\n");
var outline_f28_49_29464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Abusive head injury (shaken baby syndrome)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Unintentional head injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRIMARY EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initial assessment and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neurosurgical consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Abusive head injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Unintentional injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Child protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DEFINITIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Operative decision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Temporizing procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Timing of surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Primary evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Definitive management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6534\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6534|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/22/37231\" title=\"diagnostic image 1\">",
"      Subdural hematoma in an infant with mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/52/26432\" title=\"diagnostic image 2\">",
"      Epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/1/3094\" title=\"diagnostic image 3\">",
"      Inflicted subdural hematomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/35/9782\" title=\"diagnostic image 4\">",
"      Pediatric subdural hematoma on magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6534|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6534|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/3/25660\" title=\"table 1\">",
"      Subdural hematoma children rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/42/684\" title=\"table 2\">",
"      High risk trauma mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 3\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 4\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=related_link\">",
"      Intracranial epidural hematoma in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21575?source=related_link\">",
"      Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=related_link\">",
"      Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43767?source=related_link\">",
"      Subdural hematoma in adults: Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_49_29465="Multiple system atrophy: Clinical features and diagnosis";
var content_f28_49_29465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Multiple system atrophy: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/49/29465/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29465/contributors\">",
"     Stewart A Factor, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29465/contributors\">",
"     Christine Doss Esper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/49/29465/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29465/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/49/29465/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29465/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/49/29465/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple system atrophy (MSA) is a unifying term that brings together a group of neurodegenerative syndromes &mdash; olivopontocerebellar atrophy, striatonigral degeneration, and Shy-Drager syndrome &mdash; with similar brain pathology that are characterized by various degrees of autonomic dysfunction, cerebellar abnormalities, parkinsonism, and corticospinal degeneration.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, clinical features, and diagnosis of MSA. The prognosis and treatment of MSA and other forms of parkinsonism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6870?source=see_link\">",
"     \"Multiple system atrophy: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"     \"Clinical manifestations of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link\">",
"     \"Diagnosis of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1900, Dejerine and Thomas provided the first report of sporadic olivopontocerebellar atrophy (OPCA), a disease that later would become a part of the spectrum of MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/1\">",
"     1",
"    </a>",
"    ]. Orthostatic hypotension as a manifestation of autonomic failure was described in 1925 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/2\">",
"     2",
"    </a>",
"    ]. In 1960, Shy and Drager reported patients with autonomic features of orthostatic syncope, impotence, and bladder dysfunction who went on to develop gait abnormalities, tremor, and fasciculations among other symptoms and signs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/3\">",
"     3",
"    </a>",
"    ]. This disorder became known as the Shy-Drager syndrome.",
"   </p>",
"   <p>",
"    Also in 1960, the first cases were reported of a predominantly asymmetric parkinsonian syndrome manifested primarily by akinesia and rigidity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/4\">",
"     4",
"    </a>",
"    ]. The authors suggested that striatonigral degeneration was the pathologic correlate for these cases.",
"   </p>",
"   <p>",
"    In 1969, the term \"multiple system atrophy\" was introduced to encompass all three clinical syndromes: olivopontocerebellar atrophy, Shy-Drager syndrome, and striatonigral degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/5\">",
"     5",
"    </a>",
"    ]. Striatonigral degeneration was later redefined as MSA with predominant parkinsonism (MSA-P), while olivopontocerebellar atrophy was redefined as MSA with predominant cerebellar ataxia (MSA-C) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/6\">",
"     6",
"    </a>",
"    ]. When autonomic failure predominates, the term Shy-Drager syndrome may be used.",
"   </p>",
"   <p>",
"    The discovery that glial cytoplasmic inclusions with alpha synuclein as a major component are the pathologic hallmark of the three clinical syndromes confirmed the suspicion that they were actually different manifestations of the same disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Beginning in the 1990s, consensus groups developed guidelines to define MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/6,9-11\">",
"     6,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated annual incidence of MSA in the population &gt;50 years old is approximately 3 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/12\">",
"     12",
"    </a>",
"    ]. The estimated prevalence of MSA is between 2 to 5 cases per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of 433 pathologically proven cases of MSA, the mean age of onset was 54 years (range 31 to 78) (younger than Parkinson disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/15\">",
"     15",
"    </a>",
"    ]. Similarly, European registry studies have reported onset at a mean age of 58 to 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In these registries, MSA affects men and women about equally. However, other studies have reported that men are affected two to nine times more often than women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This finding may be secondary to earlier recognition of impotence as a major diagnostic feature in men. There is no specific racial predilection, and the disease has been reported in Caucasian, African, and Asian populations.",
"   </p>",
"   <p>",
"    There are no established environmental risk factors for MSA, but data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ]. As examples, one small case-control study found that patients with MSA had significantly more potential exposures to metals, plastics, organic solvents, and pesticides than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/21\">",
"     21",
"    </a>",
"    ], while another case-control study found that MSA was not associated with exposure to pesticides, organic solvents, or other toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main clinical features of MSA are akinetic-rigid parkinsonism, autonomic failure including urogenital dysfunction, cerebellar ataxia, and pyramidal signs in varying combinations. The onset of disease is marked by the initial clinical manifestation of any of its characteristic motor or autonomic features [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the neuropathologic changes probably begin several years before the disease becomes symptomatic. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pathology and pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Motor involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The motor presentations of MSA are classified into two separate but overlapping clinical subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/6,8,19\">",
"     6,8,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MSA with predominant parkinsonism (MSA-P) subtype",
"     </li>",
"     <li>",
"      MSA with predominant cerebellar ataxia (MSA-C) subtype",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most studies from Europe and North America, cases of MSA-P outnumber MSA-C by between two and four to one [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/18,24\">",
"     18,24",
"    </a>",
"    ]. This contrasts with studies from Japan, which report MSA-C as more common than MSA-P [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predominant motor feature can change over time with disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, the designation of MSA-P or MSA-C refers to the predominant motor problem at the time the patient is evaluated. As an example, in a European study of 437 patients from 19 centers, the proportion of patients classified as MSA-P and MSA-C was 68 and 32 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/18\">",
"     18",
"    </a>",
"    ]. However, among the entire cohort, parkinsonism and cerebellar ataxia were present in 87 and 64 percent respectively.",
"   </p>",
"   <p>",
"    Parkinsonism in MSA-P is characterized by",
"    <span class=\"nowrap\">",
"     akinesia/bradykinesia,",
"    </span>",
"    rigidity, postural instability,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an irregular jerky postural and action tremor. Up to two-thirds of patients with MSA have this tremor involving the arms. Although much less common than in idiopathic Parkinson disease, rest tremor occurs in as many as one-third of patients with MSA-P [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/16\">",
"     16",
"    </a>",
"    ]. Other warning signs that herald parkinsonism in MSA include postural instability and falls (usually within three years of motor onset), pyramidal signs, including extensor plantar responses, and rapid progression regardless of dopaminergic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8,25\">",
"     8,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional movement disorders associated with MSA-P may include stimulus-sensitive cortical myoclonus, hemiballism and chorea, and dystonia unrelated to dopaminergic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Specific types of dystonia include orofacial dystonia or dyskinesia, occasionally resembling \"risus sardonicus\" (spasm of the facial muscles producing a distorted grinning expression), and Pisa syndrome (subacute axial dystonia with severe lateral flexion of the trunk, head, and neck).",
"   </p>",
"   <p>",
"    Camptocormia (severe anterior flexion of the spine) and disproportionate anterocollis are common abnormalities of posture in MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8,29\">",
"     8,29",
"    </a>",
"    ]. The anterocollis, in particular, is characteristic of MSA although it can occur in other forms of degenerative parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of camptocormia and anterocollis in MSA is heterogeneous. While some authors believe that they represent forms of axial dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/33\">",
"     33",
"    </a>",
"    ], there are other data to suggest that myopathy is the cause, at least in certain cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Electromyography usually clarifies the picture, although biopsy may be necessary when the diagnosis is uncertain. However, it is not entirely clear what a biopsy of normal neck muscle should look like in patients with parkinsonism. &nbsp;",
"   </p>",
"   <p>",
"    In contrast to MSA-P, the motor features of MSA-C involve predominant cerebellar dysfunction that manifests as gait ataxia, limb ataxia, ataxic dysarthria, and cerebellar disturbances of eye movements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ]. Ocular abnormalities may include gaze-evoked nystagmus, impaired smooth pursuits with saccadic intrusion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ocular dysmetria.",
"   </p>",
"   <p>",
"    Dysphagia is a prominent symptom of both types of MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The speech pattern of patients with MSA is also characteristic. In addition to the hypophonic monotony often seen in idiopathic Parkinson disease, patients with MSA-P also have an increase in pitch and a quivering, strained element to their speech [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, patients with MSA-C have a more typical cerebellar scanning dysarthria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dysautonomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysautonomia is a feature of both parkinsonian and cerebellar MSA presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ]. Among patients in a large European MSA registry, symptomatic dysautonomia was present in almost all, with high rates of urinary dysfunction (83 percent) and symptomatic orthostatic hypotension (75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nearly all men with MSA develop early erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ]. Other common early symptoms include increased urinary frequency, urgency, incontinence, or incomplete bladder emptying. Although these features are also seen in idiopathic Parkinson disease, they generally begin earlier and are more profound in MSA. As an example, a study comparing 52 patients with MSA and matched patients with Parkinson disease noted that urinary dysfunction appeared in less than two years with MSA but after five years with Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/37\">",
"     37",
"    </a>",
"    ]. Detrusor underactivity with dysuria was observed within four years in 58 percent of patients with MSA and thereafter in 76 percent. In contrast, the frequency of constipation in MSA is similar to that seen in idiopathic Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the natural history of MSA, orthostatic hypotension usually emerges after urogenital symptoms appear. In a series of 100 patients with MSA, symptomatic orthostatic hypotension was present in 68 percent, and was severe in 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/19\">",
"     19",
"    </a>",
"    ]. The clinical diagnosis of probable MSA requires the presence of an orthostatic decrease of blood pressure. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sleep and breathing disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep and breathing abnormalities are common in MSA. At least two-thirds of patients have rapid eye movement (REM) sleep behavior disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/38\">",
"     38",
"    </a>",
"    ]. The content of the dreams can be vivid, violent, and frightening. The usual muscle atony in REM sleep is lost, and patients may act out their dreams. For example, patients may talk or shout during sleep and may strike out at their bed partner. This feature of MSA often precedes the motor manifestations, sometimes by decades [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/39\">",
"     39",
"    </a>",
"    ]. It tends to improve as the disease progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nocturnal or diurnal laryngeal stridor occurs in approximately one-third of patients with MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ]. It is a risk factor for sudden death in MSA. The sound of stridor is high pitched and occurs with inspiration. Patients may also experience sleep apnea and involuntary sighs or gasps during the day. Snoring may increase from premorbid level or may be new-onset. These abnormalities of breathing are uncommon in idiopathic Parkinson disease and in other atypical parkinsonian syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/24\">",
"     24",
"    </a>",
"    ]. However, REM sleep behavior disorder and obstructive sleep apnea are not specific to MSA. REM sleep behavior disorder is frequently present in idiopathic Parkinson disease and some forms of spinocerebellar ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both excessive daytime sleepiness and restless leg syndrome are present in nearly 30 percent of patients with MSA experience, rates that are similar to or greater than those seen in Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/42\">",
"     42",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29758549\">",
"    <span class=\"h2\">",
"     Cognitive function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive function in MSA tends to be relatively well preserved compared with idiopathic Parkinson disease and other atypical parkinsonian syndromes, possibly reflecting a lesser degree of cortical involvement in MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/43\">",
"     43",
"    </a>",
"    ] and the younger age of onset. Nevertheless, although cognitive impairment in MSA is uncommon, it does occur and its presence does not exclude MSA as a clinical diagnosis in patients who have classic symptoms and signs of the disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter European study evaluated a prospective cohort of 372 patients with a clinical diagnosis of MSA and found cognitive impairment in approximately 20 percent, predominantly involving diminished verbal fluency, perseveration and executive dysfunction, as seen in Parkinson disease and progressive supranuclear palsy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/44\">",
"       44",
"      </a>",
"      ]. One limitation of this report is that few patients had pathologic confirmation of the clinical diagnosis, and among those who did, the clinical diagnosis of MSA was proved wrong in 35 percent of those with cognitive impairment compared with 5 percent of those without cognitive impairment. Thus, this study probably overestimated the rate of cognitive impairment in MSA.",
"     </li>",
"     <li>",
"      A small case-control study found that patients with MSA-P had cognitive impairments involving visuospatial and constructional function, verbal fluency, and executive function, while those with MSA-C had impairments only in visuospatial and constructional function [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with MSA can develop emotional incontinence (also called pseudobulbar affect), characterized by crying inappropriately without sadness or laughing inappropriately without mirth. This manifestation is also seen, perhaps more commonly, in progressive supranuclear palsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29758569\">",
"    <span class=\"h2\">",
"     Other features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MSA may have an associated Raynaud phenomenon (an exaggerated vascular response to cold temperature or emotional stress)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cold, dusky extremities that blanch on pressure with poor circulatory return. These symptoms may be provoked by ergot drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MSA appears to be associated with high rates of anxiety and depression. In one study of 286 patients with MSA, probable depression and probable anxiety were present in 43 and 37 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/46\">",
"     46",
"    </a>",
"    ]. Olfactory dysfunction is generally mild in MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/47\">",
"     47",
"    </a>",
"    ]; a small case-control study found that olfactory dysfunction in MSA is less severe than that seen in Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain MRI in patients with MSA-P and MSA-C may reveal atrophy of the putamen, pons, and middle cerebellar peduncles [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/11,49,50\">",
"     11,49,50",
"    </a>",
"    ]. On T2 MRI sequences, signal changes include hypointensity of the posterior putamen (also described as a slit-like void), a hyperintense lateral putaminal rim, and hyperintensities of the middle cerebellar peduncles. These changes are supportive of the diagnosis of MSA rather than idiopathic Parkinson disease. However, they are not present in all patients with MSA. Furthermore, they are not specific for differentiating MSA from other atypical parkinsonian syndromes.",
"   </p>",
"   <p>",
"    The \"hot cross bun sign\" refers to hyperintense T2 signal in the shape of a cross within the pons that arises from degeneration of transverse pontocerebellar fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/11,49,51\">",
"     11,49,51",
"    </a>",
"    ]. However, this is also a nonspecific finding that has also been described in patients with other causes of parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffusion weighted MRI in patients with MSA shows increased diffusivity (high apparent diffusion coefficient values) in the putamen, a finding that is sometimes observed in progressive supranuclear palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/49\">",
"     49",
"    </a>",
"    ]. Preliminary data suggest that this technique can be used to monitor disease progression in MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positron emission tomography using (18F)fluorodeoxyglucose in patients with MSA may reveal regional glucose hypometabolism in the striatum, brainstem, and cerebellum, but the true sensitivity and specificity of these findings for differentiating MSA from PD is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Striatal dopamine transporter imaging using SPECT (eg, 123I-FP-CIT SPECT scan or DaTscan) can reliably distinguish patients with PD and other parkinsonian syndromes from controls or patients with essential tremor, but it cannot differentiate PD and the parkinsonian syndromes from one another. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnosis of Parkinson disease\", section on 'DaTscan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    I-123 metaiodobenzylguanidine imaging of the heart demonstrates postganglionic abnormalities in patients with Parkinson disease but not those with MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. This cardiac imaging technique shows promise for differentiating the two diseases, but its clinical utility has yet to be established. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of MSA is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/57\">",
"     57",
"    </a>",
"    ]. However, the presence of glial inclusions and myelin disruption in the central nervous system suggest that MSA is a primary disorder of the glia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The glial (oligodendroglial) cytoplasmic inclusions that are characteristic of MSA contain hyperphosphorylated alpha-synuclein, tau, ubiquitin, leucine-rich repeat",
"    <span class=\"nowrap\">",
"     serine/threonine-protein",
"    </span>",
"    kinase 2, and many other proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/59-63\">",
"     59-63",
"    </a>",
"    ]. Alpha-synuclein immunostaining is a sensitive marker of inclusion pathology in MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8,64\">",
"     8,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myelin degeneration may also be important in the pathophysiology of MSA. A small case-control study found a significantly greater degree of white matter hyperintensities on MRI scans from patients with MSA compared with scans from patients with Parkinson disease and healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/65\">",
"     65",
"    </a>",
"    ]. This finding could be related to the loss of myelin or to cerebral hypoperfusion from orthostatic blood pressure fluctuations in MSA.",
"   </p>",
"   <p>",
"    The pathologic distribution of glial cytoplasmic inclusions, along with the degree of neuronal loss within specific regions of the neuraxis, primarily determines the clinical presentation of MSA. In addition, neuronal cell loss appears to be significantly correlated with the pathologic burden of glial cytoplasmic inclusions and disease duration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical sites of pathologic involvement include the putamen, caudate nucleus, substantia nigra, locus ceruleus, pontine nuclei, inferior olivary nucleus, Purkinje cell layer of the cerebellum, and intermediolateral cell columns [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autonomic dysfunction is secondary to loss of cells in the intermediolateral cell columns [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/68,69\">",
"     68,69",
"    </a>",
"    ] and loss of catecholaminergic neurons of the C1 area of the ventrolateral medulla (VLM) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/70\">",
"     70",
"    </a>",
"    ]. This is manifested by severe variability in blood pressure and heart rate, orthostatic hypotension, syncope, and postprandial hypotension. Arginine-vasopressin release from magnocellular hypothalamic neurons is impaired; this may be mediated by loss of A1 neurons in the caudal VLM.",
"   </p>",
"   <p>",
"    In idiopathic Parkinson disease, positron emission tomography imaging studies have indicated that dysautonomia is caused by peripheral nervous system dysfunction, particularly myocardial sympathetic denervation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/71\">",
"     71",
"    </a>",
"    ]. In contrast, the peripheral autonomic system appears to be spared in MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/72\">",
"     72",
"    </a>",
"    ]. Some persistence of autonomic tone may be responsible for the frequently observed supine hypertension in MSA.",
"   </p>",
"   <p>",
"    Bladder abnormalities in MSA include urinary incontinence and retention. Mechanisms leading to these include detrusor hyperreflexia from loss of inhibitory input to the pontine micturition center, loss of corticotropin-releasing factor neurons in the pontine micturition area [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/70\">",
"     70",
"    </a>",
"    ], and bladder atonia primarily from severe damage to Onuf's nucleus in the sacral spinal cord; the latter is likely also the cause of erectile dysfunction in men. Bowel dysmotility is frequently seen in patients with MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/73\">",
"     73",
"    </a>",
"    ], as is thermoregulatory dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Motor abnormalities seen in MSA-P are due primarily to neuronal loss and gliosis in the substantia nigra, putamen, caudate, and globus pallidus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/4\">",
"     4",
"    </a>",
"    ]. One of the features that distinguishes MSA and other atypical parkinsonian syndromes (ie, Parkinson-plus syndromes) from idiopathic Parkinson disease is the lack of dramatic and sustained response to levodopa. The extent of putaminal involvement may determine the poor response to levodopa [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Levodopa responsiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast to MSA-P, the cerebellar ataxia and pyramidal signs that characterize the MSA-C subtype are secondary to degeneration of the cerebellar Purkinje cells, middle cerebellar peduncles, inferior olivary nuclei, basis pontis, and pontine nuclei. However, a majority of patients with MSA-P probably have subclinical loss of nigral neurons based upon findings from 123I-FP-CIT SPECT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/74\">",
"     74",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Loss of cholinergic mesopontine neurons, combined with loss of locus ceruleus neurons and preservation of rostral raphe neurons, may contribute to REM sleep abnormalities often seen in MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/70\">",
"     70",
"    </a>",
"    ]. Respiratory abnormalities may reflect loss of cholinergic neurons in the arcuate nucleus of the ventral medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/70\">",
"     70",
"    </a>",
"    ]. Respiratory stridor, abnormal nocturnal ventilation, and pseudobulbar features are possibly secondary to brainstem pathology, and may involve the nucleus ambiguus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MSA is based upon the clinical features. No laboratory or imaging studies are diagnostic, particularly since findings are often normal or equivocal in early disease.",
"   </p>",
"   <p>",
"    Levodopa responsiveness should be tested to help distinguish MSA from idiopathic Parkinson disease, although making a distinction can be complicated. For a diagnostic trial of levodopa to be valid in this setting, it is essential that the daily dose be high enough (900 to 1000 mg) in order to avoid a false negative result. Furthermore, some patients who later in the clinical course of progressive parkinsonism meet diagnostic criteria for MSA will show an early positive response to levodopa, thereby producing a falsely positive diagnosis of PD, as discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Levodopa responsiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Neuroimaging can be helpful in excluding other conditions and may show signs such as putaminal atrophy, slit-like signal change at the posterolateral putaminal margin, and hypointensity of the putamen relative to the globus pallidus. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Neuroimaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Urethral or anal sphincter electromyography can support the diagnosis of MSA if the results show chronic reinnervation with markedly prolonged motor units [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/73,75,76\">",
"     73,75,76",
"    </a>",
"    ]. However, this is a painful procedure and some studies suggest these findings are not specific for MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Levodopa responsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early stages, MSA-P may be difficult to distinguish from idiopathic Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An excellent response to dopaminergic therapy is an important supportive feature for establishing the diagnosis of idiopathic Parkinson disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H12#H12\">",
"       \"Diagnosis of Parkinson disease\", section on 'Response to dopaminergic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, a poor or unsustained response to levodopa therapy is generally observed in patients with MSA [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/66,78,79\">",
"       66,78,79",
"      </a>",
"      ]. While open-label and retrospective studies suggest transient benefit from levodopa in 30 to 50 percent of patients with MSA [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/16,19,66,78-83\">",
"       16,19,66,78-83",
"      </a>",
"      ], levodopa does not provide long-term benefit in MSA, and the loss of responsiveness can occur abruptly. However, treatment must be individualized since some patients will function better on levodopa than without it.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Levodopa responsiveness is tested by administering levodopa combined with a peripheral decarboxylase inhibitor (eg, levodopa-carbidopa) in escalating doses up to 1000 mg of levodopa daily as necessary and tolerated over a three-month period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ]. A positive response requires a clinically significant improvement in motor symptoms, defined objectively as a 30 percent or more improvement in the motor component of the Unified Parkinson Disease Rating Scale (UPDRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in idiopathic Parkinson disease, levodopa treatment may trigger or exacerbate orthostatic hypotension in patients with MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"     8",
"    </a>",
"    ]. Levodopa use also can result in motor fluctuations and dyskinesia. As an example, a case series that included 18 patients with MSA-P reported that levodopa-induced dyskinesia developed in 12 (67 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/84\">",
"     84",
"    </a>",
"    ]. Levodopa-induced dyskinesia in patients with MSA are largely restricted to the neck or face, and often consist of sustained dystonic spasms. Levodopa-induced unilateral facial dystonic spasms are particularly suggestive of MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Revised diagnostic criteria set forth in the 2008 MSA consensus statement are shown in the tables (",
"    <a class=\"graphic graphic_table graphicRef61013 \" href=\"UTD.htm?8/49/8987\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81150 \" href=\"UTD.htm?13/63/14331\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68350 \" href=\"UTD.htm?1/44/1740\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76242 \" href=\"UTD.htm?8/8/8332\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A diagnosis of definite MSA is based upon postmortem pathology showing alpha-synuclein-positive glial cytoplasmic inclusions with neurodegenerative changes in striatonigral or olivopontocerebellar structures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical diagnosis of probable MSA during life requires the following features (",
"    <a class=\"graphic graphic_table graphicRef61013 \" href=\"UTD.htm?8/49/8987\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A sporadic, progressive, adult onset (&gt;30 years old) disease",
"     </li>",
"     <li>",
"      Autonomic failure involving either urinary incontinence (inability to control the release of urine from the bladder, with erectile dysfunction in males) or an orthostatic blood pressure decrease within three minutes of standing by &ge;30 mmHg systolic or &ge;15 mmHg diastolic",
"     </li>",
"     <li>",
"      Either poorly levodopa-responsive parkinsonism (bradykinesia with rigidity, tremor, or postural instability)",
"      <strong>",
"       or",
"      </strong>",
"      a cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical diagnosis of possible MSA requires a sporadic, progressive, adult onset disease with either parkinsonism or cerebellar ataxia and at least one feature suggesting dysautonomia plus one additional supporting feature (",
"    <a class=\"graphic graphic_table graphicRef81150 \" href=\"UTD.htm?13/63/14331\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68350 \" href=\"UTD.htm?1/44/1740\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Neuroimaging criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging correlates of MSA lack sufficient sensitivity and specificity to be used as reliable markers of probable MSA. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Neuroimaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nevertheless, current diagnostic criteria regard atrophy of putamen, middle cerebellar peduncle, or pons on MRI as supportive features for possible MSA-P or MSA-C [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/11,49\">",
"     11,49",
"    </a>",
"    ]. Additional supportive features for MSA subtypes are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a patient with parkinsonian features but no cerebellar ataxia, hypometabolism of putamen, brainstem, or cerebellum on (18F)fluorodeoxyglucose-positron emission tomography (FDG-PET) is considered to be a supportive feature for possible MSA-P.",
"     </li>",
"     <li>",
"      In a patient with cerebellar ataxia lacking parkinsonian features, two additional imaging features are considered to be supportive for possible MSA-C:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypometabolism of the putamen on FDG-PET",
"     </li>",
"     <li>",
"      Presynaptic dopaminergic denervation in the striatum on functional imaging with single photon emission computed tomography (SPECT) or PET",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish MSA from idiopathic Parkinson disease and from other atypical parkinsonian syndromes, mainly progressive supranuclear palsy and corticobasal degeneration. In our clinical experience, MSA with predominant parkinsonism (MSA-P) is the parkinsonian syndrome most commonly misdiagnosed as progressive supranuclear palsy and correctly diagnosed only at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of Parkinson disease\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary feature that clinically distinguishes MSA-P from idiopathic Parkinson disease in most cases is the lack of a sustained and dramatic reduction in clinical symptoms and signs with levodopa therapy (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Levodopa responsiveness'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Additional clues include the presence of other characteristic features of MSA, such as autonomic failure, the jerky postural tremor, ataxia (in MSA-C), and pyramidal tract signs",
"     </li>",
"     <li>",
"      Vertical eye movement abnormalities suggest progressive supranuclear palsy",
"     </li>",
"     <li>",
"      Apraxia suggests corticobasal ganglionic degeneration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is overlap among these conditions. MSA may sometimes present with the phenotype of progressive supranuclear palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/86\">",
"     86",
"    </a>",
"    ]. In addition, patients with a pure akinetic-rigid syndrome may be impossible to diagnose.",
"   </p>",
"   <p>",
"    Among patients with idiopathic adult-onset cerebellar ataxia, 21 to 33 percent will ultimately turn out to have MSA-C [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/24,87,88\">",
"     24,87,88",
"    </a>",
"    ]. Late-onset Friedreich ataxia and spinocerebellar ataxia types 2 and 3 can present as a combination of cerebellar and parkinsonian features. These disorders may be misdiagnosed as MSA-C or vice-versa [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/87\">",
"     87",
"    </a>",
"    ]. However, MSA-C typically has onset at an older age and progresses faster than the hereditary forms of spinocerebellar ataxia.",
"   </p>",
"   <p>",
"    Pure autonomic failure should be considered if autonomic symptoms are the predominant feature of the disorder and motor involvement is limited or absent. Pure autonomic failure is associated with slower functional deterioration and a better prognosis than MSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29465/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mitochondrial disorders also affect multiple systems, but often include other neurologic features such as myopathy, optic neuropathy or retinopathy, and deafness. Systemic features of mitochondrial disorders may include cardiomyopathy and diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term \"multiple system atrophy\" (MSA) encompasses three clinical syndromes: olivopontocerebellar atrophy, Shy-Drager syndrome, and striatonigral degeneration. Striatonigral degeneration is now termed MSA with predominant parkinsonism (MSA-P), and olivopontocerebellar atrophy is now termed MSA with predominant cerebellar ataxia (MSA-C). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Historical background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimated annual incidence of MSA in the population &gt;50 years old is approximately 3 per 100,000. The mean age of onset ranges from 54 to 60 years. There appears to be no racial or gender predilection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main clinical features of MSA are akinetic-rigid parkinsonism, autonomic failure, urogenital dysfunction, cerebellar ataxia, and pyramidal signs in varying combinations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The motor features of MSA-P are characterized by",
"      <span class=\"nowrap\">",
"       akinesia/bradykinesia,",
"      </span>",
"      rigidity, postural instability,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an irregular jerky postural and action tremor. The motor features of MSA-C involve predominant cerebellar dysfunction that manifests as gait ataxia, limb ataxia, ataxic dysarthria, and cerebellar disturbances of eye movements. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Motor involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dysautonomia is a feature of both MSA-P and MSA-C. Nearly all men with MSA develop early erectile dysfunction. Other common early MSA symptoms include increased urinary frequency, urgency, incontinence, or incomplete bladder emptying. Orthostatic hypotension usually emerges after urogenital symptoms appear. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dysautonomia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of MSA is unknown. Glial cytoplasmic inclusions are the pathologic hallmark of MSA and contain alpha-synuclein, tau, and ubiquitin. Typical sites of pathologic involvement include the putamen, caudate nucleus, substantia nigra, locus ceruleus, pontine nuclei, inferior olivary nucleus, Purkinje cell layer of the cerebellum, and intermediolateral cell columns. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pathology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of MSA is based upon the clinical features. No laboratory or imaging studies are diagnostic. Lack of sustained response to levodopa can help to distinguish MSA from idiopathic Parkinson disease, but transient benefit from levodopa is observed in 30 to 50 percent of patients with MSA. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to distinguish MSA from idiopathic Parkinson disease and other atypical parkinsonian syndromes (progressive supranuclear palsy and corticobasal degeneration). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/1\">",
"      Dejerine, J, Thomas, A. L'atrophie olivo-ponto-c&eacute;r&eacute;belleuse. Nouvelle iconographie de la Salp&ecirc;tri&egrave;re 1900; 13:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/2\">",
"      Bradbury, S, Eggleston, C. Postural hypotension: a report of three cases. American Heart Journal 1925; 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/3\">",
"      SHY GM, DRAGER GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol 1960; 2:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/4\">",
"      van der Eecken, H, Adams, RD, van Bogaert, L. Striopallidal-nigral degeneration. An hitherto undescribed lesion in paralysis agitans. J Neuropathol Exp Neurol 1960; 19:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/5\">",
"      Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969; 32:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/6\">",
"      Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/7\">",
"      Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989; 94:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/8\">",
"      Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/9\">",
"      Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996; 46:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/10\">",
"      Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998; 8:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/11\">",
"      Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/12\">",
"      Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/13\">",
"      Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/14\">",
"      Tison F, Yekhlef F, Chrysostome V, Sourgen C. Prevalence of multiple system atrophy. Lancet 2000; 355:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/15\">",
"      Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997; 48:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/16\">",
"      Geser F, Seppi K, Stampfer-Kountchev M, et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm 2005; 112:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/17\">",
"      W&uuml;llner U, Schmitz-H&uuml;bsch T, Abele M, et al. Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease. J Neural Transm 2007; 114:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/18\">",
"      K&ouml;llensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/19\">",
"      Wenning GK, Ben Shlomo Y, Magalh&atilde;es M, et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117 ( Pt 4):835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/20\">",
"      Vanacore N. Epidemiological evidence on multiple system atrophy. J Neural Transm 2005; 112:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/21\">",
"      Nee LE, Gomez MR, Dambrosia J, et al. Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res 1991; 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/22\">",
"      Vidal JS, Vidailhet M, Elbaz A, et al. Risk factors of multiple system atrophy: a case-control study in French patients. Mov Disord 2008; 23:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/23\">",
"      Stefanova N, B&uuml;cke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/24\">",
"      Quinn NP. How to diagnose multiple system atrophy. Mov Disord 2005; 20 Suppl 12:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/25\">",
"      Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002; 125:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/26\">",
"      Chen R, Ashby P, Lang AE. Stimulus-sensitive myoclonus in akinetic-rigid syndromes. Brain 1992; 115 ( Pt 6):1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/27\">",
"      Salazar G, Valls-Sol&eacute; J, Mart&iacute; MJ, et al. Postural and action myoclonus in patients with parkinsonian type multiple system atrophy. Mov Disord 2000; 15:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/28\">",
"      Steiger MJ, Pires M, Scaravilli F, et al. Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration. Mov Disord 1992; 7:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/29\">",
"      Quinn N. Disproportionate antecollis in multiple system atrophy. Lancet 1989; 1:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/30\">",
"      Kashihara K, Ohno M, Tomita S. Dropped head syndrome in Parkinson's disease. Mov Disord 2006; 21:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/31\">",
"      Spuler S, Krug H, Klein C, et al. Myopathy causing camptocormia in idiopathic Parkinson's disease: a multidisciplinary approach. Mov Disord 2010; 25:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/32\">",
"      Margraf NG, Wrede A, Rohr A, et al. Camptocormia in idiopathic Parkinson's disease: a focal myopathy of the paravertebral muscles. Mov Disord 2010; 25:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/33\">",
"      Jankovic J. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord 2010; 25:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/34\">",
"      Askmark H, Eeg-Olofsson K, Johansson A, et al. Parkinsonism and neck extensor myopathy: a new syndrome or coincidental findings? Arch Neurol 2001; 58:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/35\">",
"      Lava NS, Factor SA. Focal myopathy as a cause of anterocollis in Parkinsonism. Mov Disord 2001; 16:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/36\">",
"      Berciano J. Olivopontocerebellar atrophy. A review of 117 cases. J Neurol Sci 1982; 53:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/37\">",
"      Bloch F, Pichon B, Bonnet AM, et al. Urodynamic analysis in multiple system atrophy: characterisation of detrusor-sphincter dyssynergia. J Neurol 2010; 257:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/38\">",
"      Plazzi G, Corsini R, Provini F, et al. REM sleep behavior disorders in multiple system atrophy. Neurology 1997; 48:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/39\">",
"      Claassen DO, Josephs KA, Ahlskog JE, et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010; 75:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/40\">",
"      Friedman JH, Fernandez HH, Sudarsky LR. REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3). Mov Disord 2003; 18:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/41\">",
"      Iranzo A, Santamar&iacute;a J, Rye DB, et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005; 65:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/42\">",
"      Moreno-L&oacute;pez C, Santamar&iacute;a J, Salamero M, et al. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol 2011; 68:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/43\">",
"      Bak TH, Crawford LM, Hearn VC, et al. Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 2005; 11:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/44\">",
"      Brown RG, Lacomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010; 133:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/45\">",
"      Kawai Y, Suenaga M, Takeda A, et al. Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 2008; 70:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/46\">",
"      Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010; 25:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/47\">",
"      Katzenschlager R, Lees AJ. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol 2004; 17:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/48\">",
"      Kikuchi A, Baba T, Hasegawa T, et al. Differentiating Parkinson's disease from multiple system atrophy by [123I] meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. Parkinsonism Relat Disord 2011; 17:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/49\">",
"      Brooks DJ, Seppi K, Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009; 24:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/50\">",
"      Lang AE, Curran T, Provias J, Bergeron C. Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. Can J Neurol Sci 1994; 21:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/51\">",
"      Massano J, Costa F, Nadais G. Teaching neuroImage: MRI in multiple system atrophy: \"hot cross bun\" sign and hyperintense rim bordering the putamina. Neurology 2008; 71:e38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/52\">",
"      Muqit MM, Mort D, Miskiel KA, Shakir RA. \"Hot cross bun\" sign in a patient with parkinsonism secondary to presumed vasculitis. J Neurol Neurosurg Psychiatry 2001; 71:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/53\">",
"      B&uuml;rk K, Skalej M, Dichgans J. Pontine MRI hyperintensities (\"the cross sign\") are not pathognomonic for multiple system atrophy (MSA). Mov Disord 2001; 16:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/54\">",
"      Pellecchia MT, Barone P, Vicidomini C, et al. Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. Mov Disord 2011; 26:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/55\">",
"      Marini C, Bandettini di Poggio M, Pomposelli E, et al. Whole body and cardiac metaiodobenzylguanidine kinetics in Parkinson disease and multiple system atrophy: implications for the diagnostic role of imaging. Clin Nucl Med 2010; 35:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/56\">",
"      Nagayama H, Ueda M, Yamazaki M, et al. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010; 25:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/57\">",
"      Wenning GK, Stefanova N, Jellinger KA, et al. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 2008; 64:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/58\">",
"      Matsuo A, Akiguchi I, Lee GC, et al. Myelin degeneration in multiple system atrophy detected by unique antibodies. Am J Pathol 1998; 153:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/59\">",
"      Cairns NJ, Atkinson PF, Hanger DP, et al. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. Neurosci Lett 1997; 230:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/60\">",
"      Dickson DW, Liu W, Hardy J, et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 1999; 155:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/61\">",
"      Irving EA, Nicoll J, Graham DI, Dewar D. Increased tau immunoreactivity in oligodendrocytes following human stroke and head injury. Neurosci Lett 1996; 213:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/62\">",
"      Probst-Cousin S, Bergmann M, Kuchelmeister K, et al. Ubiquitin-positive inclusions in different types of multiple system atrophy: distribution and specificity. Pathol Res Pract 1996; 192:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/63\">",
"      Jellinger KA, Lantos PL. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol 2010; 119:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/64\">",
"      Wakabayashi K, Kawachi I, Toyoshima Y, Takahashi H. [Occurrence of argyrophilic grains in multiple system atrophy: histopathological examination of 26 autopsy cases]. No To Shinkei 1999; 51:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/65\">",
"      Umoto M, Miwa H, Ando R, et al. White matter hyperintensities in patients with multiple system atrophy. Parkinsonism Relat Disord 2012; 18:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/66\">",
"      Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004; 127:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/67\">",
"      Lantos PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol 1998; 57:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/68\">",
"      Gray F, Vincent D, Hauw JJ. Quantitative study of lateral horn cells in 15 cases of multiple system atrophy. Acta Neuropathol 1988; 75:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/69\">",
"      Oppenheimer DR. Lateral horn cells in progressive autonomic failure. J Neurol Sci 1980; 46:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/70\">",
"      Benarroch EE. Brainstem in multiple system atrophy: clinicopathological correlations. Cell Mol Neurobiol 2003; 23:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/71\">",
"      Goldstein DS, Holmes CS, Dendi R, et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002; 58:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/72\">",
"      Parikh SM, Diedrich A, Biaggioni I, Robertson D. The nature of the autonomic dysfunction in multiple system atrophy. J Neurol Sci 2002; 200:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/73\">",
"      Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time, sphincter EMG, and rectoanal videomanometry in multiple system atrophy. Mov Disord 2004; 19:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/74\">",
"      Mu&ntilde;oz E, Iranzo A, Rauek S, et al. Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C). J Neurol 2011; 258:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/75\">",
"      Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997; 20:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/76\">",
"      Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 1994; 151:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/77\">",
"      Libelius R, Johansson F. Quantitative electromyography of the external anal sphincter in Parkinson's disease and multiple system atrophy. Muscle Nerve 2000; 23:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/78\">",
"      Hughes AJ, Colosimo C, Kleedorfer B, et al. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992; 55:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/79\">",
"      Parati EA, Fetoni V, Geminiani GC, et al. Response to L-DOPA in multiple system atrophy. Clin Neuropharmacol 1993; 16:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/80\">",
"      Albanese A, Colosimo C, Bentivoglio AR, et al. Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry 1995; 59:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/81\">",
"      Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990; 113 ( Pt 6):1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/82\">",
"      Fetoni V, Genitrini S, Monza D, et al. Variations in axial, proximal, and distal motor response to L-dopa in multisystem atrophy and Parkinson's disease. Clin Neuropharmacol 1997; 20:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/83\">",
"      Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990; 13:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/84\">",
"      Boesch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002; 72:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/85\">",
"      Quinn, N. Unilateral facial dystonia in multiple system atrophy. Mov Disord 1992; 7 Suppl 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/86\">",
"      Murphy MA, Friedman JH, Tetrud JW, Factor SA. Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases. J Clin Neurosci 2005; 12:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/87\">",
"      Abele M, B&uuml;rk K, Sch&ouml;ls L, et al. The aetiology of sporadic adult-onset ataxia. Brain 2002; 125:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/88\">",
"      Gilman S, Little R, Johanns J, et al. Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy. Neurology 2000; 55:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29465/abstract/89\">",
"      Mabuchi N, Hirayama M, Koike Y, et al. Progression and prognosis in pure autonomic failure (PAF): comparison with multiple system atrophy. J Neurol Neurosurg Psychiatry 2005; 76:947.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4890 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-965172F715-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29465=[""].join("\n");
var outline_f28_49_29465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Motor involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dysautonomia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sleep and breathing disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29758549\">",
"      Cognitive function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29758569\">",
"      Other features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Levodopa responsiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Neuroimaging criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4890\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4890|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/49/8987\" title=\"table 1\">",
"      DX probable MSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/63/14331\" title=\"table 2\">",
"      Dx possible MSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/44/1740\" title=\"table 3\">",
"      Addtl features possible MSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/8/8332\" title=\"table 4\">",
"      Support nonsupport dx MSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=related_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6870?source=related_link\">",
"      Multiple system atrophy: Prognosis and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_49_29466="Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents";
var content_f28_49_29466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/49/29466/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29466/contributors\">",
"     Fabien Maldonado, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29466/contributors\">",
"     Andrew H Limper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29466/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/49/29466/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29466/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/49/29466/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29466/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/49/29466/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/49/29466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse drug reactions (ADRs) due to antineoplastic agents are a common form of iatrogenic injury, and the lungs are a frequent target [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. While some antineoplastic agent-induced ADRs are potentially preventable (particularly those that are related to cumulative dosing), many are idiosyncratic and unpredictable.",
"   </p>",
"   <p>",
"    Increasingly, cancer treatment is selected based upon an individual tumor's molecular features, a practice termed molecularly targeted therapy. Examples include use of the monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for breast cancers that over-express HER2;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , a tyrosine kinase (TK) inhibitor, for gastrointestinal stromal tumors with mutations in the KIT receptor TK, as well as chronic myelogenous leukemia (where the target is the Bcr-Abl fusion protein); and anti-epidermal growth factor receptor (EGFR) monoclonal antibodies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    for metastatic colorectal tumors lacking mutations in the K ras oncogene. Many of these agents are associated with lung toxicity.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the incidence and specific patterns of lung toxicity seen with molecularly targeted agents used for cancer therapy. A general discussion of the clinical presentation, pathogenesis, diagnosis, differential diagnosis, and treatment of pulmonary toxicity associated with the use of antineoplastic agents is covered separately, as is lung toxicity associated with conventional cytotoxic chemotherapy agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17050?source=see_link\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SMALL MOLECULE TYROSINE KINASE INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anti-EGFR agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     Gefitinib",
"    </a>",
"    (Iressa) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    (Tarceva) are orally active small molecule inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK). They are primarily used in the treatment of advanced non-small small lung cancer (NSCLC). Gefitinib is only available in the United States for patients who have already shown a response to this agent; it is widely used in Asia.",
"   </p>",
"   <p>",
"    Lung toxicity is reported with both agents, although the mechanism is unclear. EGFR is expressed on type II pneumocytes and involved in alveolar wall repair. EGFR TK inhibitors, by interrupting alveolar repair mechanisms, may potentiate the effect of lung injury due to other causes, including sepsis, radiation therapy, prior lung injury, and other medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H3#H3\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Gefitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     Gefitinib",
"    </a>",
"    -related interstitial lung disease (ILD) is uncommon overall. For unclear reasons, the incidence varies geographically; incidence rates are higher in Asian (2 to 6 percent) as compared to Caucasian populations (0.2 to 0.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/4,5,9-13\">",
"     4,5,9-13",
"    </a>",
"    ], and lower in African Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/14\">",
"     14",
"    </a>",
"    ]. Lung toxicity is fatal in 31 to 45 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/4,9,15\">",
"     4,9,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    -associated ILD were addressed in a cohort and nested case-control study of Japanese patients treated for NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/4\">",
"     4",
"    </a>",
"    ]. Older age, poor performance status, smoking, a recent diagnosis of NSCLC, preexisting chronic ILD with extensive infiltrates on CT, and concurrent cardiac disease all increased the risk for ILD. A prior history of fibrotic lung disease or concurrent chest irradiation may also be aggravating factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/4,5,9,16-19\">",
"     4,5,9,16-19",
"    </a>",
"    ]. An interaction between smoking and gender was suggested in an analysis of 1976 Japanese patients receiving gefitinib for NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/16\">",
"     16",
"    </a>",
"    ]. The prevalence of ILD ranged from 0.4 percent for women without a history of smoking to 6.6 percent in male smokers.",
"   </p>",
"   <p>",
"    In a postmarketing analysis of 50,000 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    for NSCLC, 408 cases of ILD were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/9\">",
"     9",
"    </a>",
"    ]. The most common presentation was acute dyspnea with or without cough or low grade fever. Symptoms often became severe within a short time, and hospitalization was required. The median time to onset of symptoms was 24 to 31 days in Japanese and 42 days in American patients. One-third of cases were fatal.",
"   </p>",
"   <p>",
"    Radiographic appearance was assessed in a study of 70 patients with confirmed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    -induced lung toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/10\">",
"     10",
"    </a>",
"    ]. There were four predominant patterns on CT scan: non-specific ground glass opacities (n = 29), multifocal areas of airspace consolidation (n = 7), patchy ground-glass infiltrates with septal thickening (n = 3), and extensive ground-glass infiltrates or airspace consolidation with traction bronchiectasis (n = 20) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/10\">",
"     10",
"    </a>",
"    ]. The remaining 11 patients had nonspecific radiographic findings.",
"   </p>",
"   <p>",
"    The pattern, distribution, and extent of the findings correlated with outcomes. Overall, 31 of the 70 patients died (44 percent), and the mortality was especially high (75 percent) among patients with extensive ground-glass infiltrates or airspace consolidation, a finding that is thought to reflect diffuse alveolar damage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the cases that have been subject to biopsy, the most common histologic patterns are diffuse alveolar damage, interstitial inflammation with and without fibrosis, and organizing pneumonia; alveolar hemorrhage has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/11,15,16,18\">",
"     11,15,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is largely supportive, with immediate and permanent discontinuation of the drug. In addition, some suggest that the early use of glucocorticoid therapy is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/20\">",
"     20",
"    </a>",
"    ]; however, the efficacy of glucocorticoid treatment has only been examined in retrospective series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report detailing 70 cases of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      -related ILD, glucocorticoids were administered to 66; additional antibiotic treatment did not increase the proportion of patients whose ILD improved (18 and 61 percent of those treated with and without antibiotics, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a smaller series, two of four patients with NSCLC who developed acute interstitial pneumonia while receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      died despite the use of high-dose glucocorticoids; the other two responded [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Successful use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    in a patient who developed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    -related ILD is reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Erlotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited information is available regarding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    -induced lung toxicity. ILD, which is sometimes fatal, has been reported in about 0.8 percent of patients receiving erlotinib [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/23-26\">",
"     23-26",
"    </a>",
"    ], but the true incidence is unknown. In placebo-controlled randomized trials of erlotinib in advanced NSCLC, rates of cough, dyspnea, and ILD have been similar in the erlotinib and control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]. However, ILD may have been underdiagnosed for several reasons. ILD requires diagnostic testing, which may not have been undertaken in patients who developed respiratory symptoms during antineoplastic therapy, possibly because were assumed to be due to advanced NSCLC. Furthermore, it can be difficult to distinguish progressive cancer, particularly of the bronchioloalveolar subtype, from drug-induced ILD.",
"   </p>",
"   <p>",
"    Whether the concurrent use of cytotoxic chemotherapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    increases the risk of ILD is also unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In the TRIBUTE trial (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    with or without erlotinib for NSCLC), the frequencies of dyspnea and cough during treatment were similar in the erlotinib and placebo groups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/30\">",
"     30",
"    </a>",
"    ]. Five severe ILD-like cases occurred in the erlotinib arm versus one event in the placebo arm; all ILD-like events were fatal.",
"   </p>",
"   <p>",
"    In a later independent review of fatal serious ADRs from the TRIBUTE trial, three fatal cases of",
"    <span class=\"nowrap\">",
"     pneumonia/ILD",
"    </span>",
"    in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    were felt to be directly attributable to the drug (incidence 0.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/31\">",
"     31",
"    </a>",
"    ]. The only patient to undergo lung biopsy had organizing pneumonia. Others cases subjected to biopsy have shown diffuse alveolar damage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation is typically acute with dyspnea, sometimes associated with cough or low-grade fever, which often becomes severe within a short time and requires hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/32\">",
"     32",
"    </a>",
"    ]. The median time to occurrence of ILD in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    in this report was 47 days (range five days to more than nine months). As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    , preexisting pulmonary fibrosis may be a risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fatalities are reported, although the mortality rate among patients who develop ILD while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/29,31,32\">",
"     29,31,32",
"    </a>",
"    ]. In one report, one of four patients who developed lung toxicity during erlotinib monotherapy for NSCLC died [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is largely supportive with discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    . Glucocorticoid therapy may lead to clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/34\">",
"     34",
"    </a>",
"    ], but fatalities still occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/28,29,31\">",
"     28,29,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lapatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , lung toxicity appears to be very rare with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    , a dual inhibitor of EGFR-I and HER2 (EGFR-2). There is only one case report of interstitial pneumonitis developing in a patient treated with lapatinib and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    develop lung toxicity, usually within the first two to three months of therapy. The risk is higher in patients with preexisting lung disease and in smokers. About one-third of patients who develop interstitial lung disease while being treated with gefitinib die of this complication; the mortality rate in patients who develop ILD while receiving erlotinib is not well characterized but is likely similar to gefitinib based on available information.",
"   </p>",
"   <p>",
"    Treatment is largely supportive, with immediate drug discontinuation, administration of supplemental oxygen, empiric antibiotics, and mechanical ventilation as clinically indicated. Systemic glucocorticoids are usually recommended, although the evidence to support their use is largely anecdotal, and fatalities still occur despite empiric treatment with high-dose glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bcr-Abl tyrosine kinase inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    , an orally active inhibitor of Bcr-Abl, KIT, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases (TKs), is an effective treatment for gastrointestinal stromal tumors and Philadelphia-chromosome-positive chronic myelogenous leukemia (Ph+CML).",
"   </p>",
"   <p>",
"    Most of the lung complications reported during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy are related to fluid retention, a common side effect [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. However, peripheral and periorbital edema are far more frequent manifestations of fluid retention than are pleural or pericardial effusions and pulmonary edema.",
"   </p>",
"   <p>",
"    Rare cases of acute pneumonia with and without eosinophilic infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/39-41\">",
"     39-41",
"    </a>",
"    ], and subacute interstitial pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/42,43\">",
"     42,43",
"    </a>",
"    ] are reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    treatment. Lung toxicity has been reported with doses as low as 100 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest series consists of 27 cases of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -induced ILD reported to Novartis in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/44\">",
"     44",
"    </a>",
"    ]. The median time to development of ILD was 49 days (range 10 to 282). The most common clinical presentation was the subacute development of low-grade fever, dry cough, and progressive dyspnea on exertion, with or without hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/39,45,46\">",
"     39,45,46",
"    </a>",
"    ]. Preexisting lung disease was present in 11 of 27 patients (41 percent) in the Japanese series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, radiographic studies show bilateral diffuse or patchy ground glass opacities, consolidation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fine nodular opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/44\">",
"     44",
"    </a>",
"    ]. Findings on bronchoalveolar lavage (BAL) include lymphocytes, foamy macrophages,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/43,44,46\">",
"     43,44,46",
"    </a>",
"    ]. Bronchial biopsies may show pulmonary alveolar proteinosis, interstitial inflammation and fibrosis, alveolitis, or organization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/41,44,46\">",
"     41,44,46",
"    </a>",
"    ]. Peripheral eosinophilia may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the syndrome may resolve with drug discontinuation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/41,46\">",
"     41,46",
"    </a>",
"    ], most cases require glucocorticoid therapy for resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/39,42,45,47,48\">",
"     39,42,45,47,48",
"    </a>",
"    ]. Only one fatality has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rechallenge",
"      </strong>",
"      &ndash; The decision as to whether to restart",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in a patient who has had pulmonary toxicity must be made on a case by case basis, and should be based upon the severity of the reaction, and the availability of alternative therapies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"       \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Rechallenge does not always prompt a recurrence of lung injury [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/44,50\">",
"       44,50",
"      </a>",
"      ]. In the Japanese series described above, imatinib was readministered to 11 patients after interstitial lung disease improved; four had a recurrence of lung toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/44\">",
"       44",
"      </a>",
"      ]. However, in general, rechallenge is not recommended, unless other therapeutic options are not available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dasatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second generation Bcr-Abl tyrosine kinase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    inhibit Bcr-Abl, KIT, and PDGFR, as well as other signaling pathways including SRC kinases; they are used only for the treatment of Ph+CML.",
"   </p>",
"   <p>",
"    Of the Bcr-Abl TK inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    has been associated with the highest frequency of pulmonary side effects. During treatment with dasatinib, pleural, pulmonary vascular, and lung parenchymal abnormalities can develop separately or simultaneously.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pleural effusion &ndash;",
"      </strong>",
"      Pleural effusions are more commonly seen in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and may be bilateral or unilateral. Between 10 and 35 percent of patients treated with dasatinib in clinical trials developed pleural effusions, most often exudative and lymphocyte predominant [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/51-55\">",
"       51-55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H328401472#H328401472\">",
"       \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Pulmonary complications'",
"      </a>",
"      .) &nbsp;",
"      <br/>",
"      <br/>",
"      In one report of 172 elderly patients treated with dasatinib for Ph+CML, pleural effusions occurred in 30 percent, were recurrent in 15 percent, and required treatment discontinuation in 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/53\">",
"       53",
"      </a>",
"      ]. The mean time to onset of the pleural effusion was 11 months (range 3.6 to 18.6 months). Only the presence of concomitant pulmonary disease and higher initial daily dose (140 versus 100 mg) were significant risk factors. When the patients on the lower dose of dasatinib were analyzed separately, underlying pulmonary disease was no longer identified as a risk factor. &nbsp;",
"      <br/>",
"      <br/>",
"      Altering the dasatinib regimen from 70 mg twice daily to 100 mg daily reduces the risk of pleural effusion, without affecting antitumor efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/56\">",
"       56",
"      </a>",
"      ]. Optimal treatment of dasatinib-related pleural effusions, when they occur, is not known. In case series, treatment has included systemic glucocorticoids, diuretics, thoracentesis, and dasatinib interruption or discontinuation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/51,53,57,58\">",
"       51,53,57,58",
"      </a>",
"      ]. Rarely, pleurodesis has been used [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/58\">",
"       58",
"      </a>",
"      ]. Combinations of the above therapies have also been employed.",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary arterial hypertension",
"      </strong>",
"      &ndash; Case reports describe reversible pulmonary arterial hypertension (PAH) in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      for Ph+CML [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/59-63\">",
"       59-63",
"      </a>",
"      ]. Data from the French Pharmacovigilance Agency suggest that the incidence of PAH among patients treated with dasatinib is low (0.45 percent), although this is likely an underestimate due to incomplete case finding [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients typically present with exertional dyspnea, fatigue, tachypnea, and peripheral edema, developing after 8 to 48 months of dasatinib therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/59-63\">",
"       59-63",
"      </a>",
"      ]. Reported pulmonary artery pressures (PAP) by right heart catheterization are 53 to 66 mmHg (systolic) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/59-62\">",
"       59-62",
"      </a>",
"      ] and 25 to 50 mmHg (mean) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/61,63\">",
"       61,63",
"      </a>",
"      ]. Although a few patients have experienced full clinical and hemodynamic recovery, the majority have not recovered completely after follow-up that ranges from 3 to 36 months (median 9 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/59-63\">",
"       59-63",
"      </a>",
"      ]. In one case series, an endothelin receptor antagonist was administered to two patients and a calcium channel blocker to a third [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/63\">",
"       63",
"      </a>",
"      ]; it is unclear whether subsequent improvement was related to these therapies, dasatinib discontinuation, or both.",
"      <br/>",
"      <br/>",
"      Patients who develop dasatinib-induced PAH should not be rechallenged with the drug. Safe treatment with another second-generation tyrosine kinase inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      , has been described in eight patients with dasatinib-associated PAH [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/59,60,62,63\">",
"       59,60,62,63",
"      </a>",
"      ]. An additional patient with severe PAH at presentation experienced progressive respiratory failure after stopping dasatinib but while taking nilotinib, although it was unclear whether nilotinib was contributory [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/63\">",
"       63",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There are no reports of PAH with the other Bcr-Abl TK inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/63\">",
"       63",
"      </a>",
"      ], and no reports of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      treatment after development of dasatinib-induced PAH. In one report, one patient received two years of imatinib followed by two and a half years of dasatinib prior to development of PAH, which was presumably secondary to dasatinib and not imatinib [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/59\">",
"       59",
"      </a>",
"      ]. It is hypothesized that PAH may represent an &ldquo;off-target&rdquo; side effect of dasatinib related to its interaction with over 40 kinases, many of which are not affected by the more selective nilotinib and imatinib [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/59,64\">",
"       59,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pneumoniti",
"      </strong>",
"      s &ndash; Lung parenchymal changes are rarely described among patients who develop respiratory symptoms while receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. In a series of 40 patients with CML, nine (23 percent) developed lung abnormalities from 29 to 500 days after starting dasatinib [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/65\">",
"       65",
"      </a>",
"      ]. Three had parenchymal changes (ground glass or alveolar opacities and septal thickening) without pleural effusion, five had both pleural and parenchymal disease, and one had bilateral pleural effusions alone. In five patients, BAL fluid analysis showed lymphocytosis or neutrophilia. Bronchial biopsy was only undertaken in one patient and was nondiagnostic.",
"      <br/>",
"      <br/>",
"      Dasatinib treatment was held in eight patients, while one received glucocorticoid therapy with no dasatinib interruption. Dasatinib-associated lung abnormalities resolved completely in seven patients and partially resolved in two. Among the seven patients with radiographic parenchymal changes, six had complete resolution within three months of dasatinib interruption (n = 5) or the addition of glucocorticoid therapy (n = 1); one had persistent septal thickening. There were no fatalities.",
"     </li>",
"     <li>",
"      <strong>",
"       Rechallenge &ndash;",
"      </strong>",
"      The decision as to whether to restart",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      in a patient who has had pulmonary toxicity (other than pulmonary arterial hypertension, which should prompt permanent discontinuation of the drug) must be made on a case by case basis, and should be based upon the severity of the reaction, and the availability of alternative therapies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"       \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      One option is to restart the drug at a lower dose. In the series described above, only one of four patients who had reintroduction of dasatinib at a lower dose following resolution of radiographic changes had recurrence of respiratory symptoms, manifest as bilateral pleural effusions, without a parenchymal component [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16655010\">",
"    <span class=\"h3\">",
"     Nilotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    targets Bcr-Abl, KIT, and PDGFR, but not SRC kinases. Pleural effusion and other pulmonary toxicities are rare with nilotinib. In one trial, pleural effusion was noted in &lt;1 percent of patients treated with nilotinib for Ph+CML [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9315266\">",
"    <span class=\"h3\">",
"     Bosutinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    is the newest second-generation agent that targets Bcr-Abl and Src pathways, but not KIT or PDGFR. Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , it is approved only for Ph+CML in adult patients.&nbsp;The main pulmonary toxicity is pleural effusion, which in one study of 118 patients, occurred in nine (8 percent), seven of whom had a history of developing pleural effusions on prior Bcr-Abl TK inhibitors such as dasatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11220652\">",
"    <span class=\"h2\">",
"     Crizotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     Crizotinib",
"    </a>",
"    , an orally active inhibitor or the anaplastic lymphoma kinase (ALK), is approved for treatment of advanced or metastatic non-small cell lung cancer if the tumor contains a characteristic EML4-ALK fusion oncogene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link&amp;anchor=H11#H11\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\", section on 'Crizotinib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In phase II clinical trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    was associated with severe, life-threatening, or fatal pneumonitis in four of 255 patients (1.6 percent), all of which developed within two months of treatment initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/70\">",
"     70",
"    </a>",
"    ]. Permanent discontinuation is advised in the event of treatment-related pneumonitis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     AGENTS TARGETING VEGF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of a blood supply is a necessary prerequisite for tumor growth. The dominant factor controlling angiogenesis is vascular endothelial growth factor (VEGF). Inhibition of VEGF by a variety of methods produces a marked antitumor response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link\">",
"     \"Overview of angiogenesis inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three different approaches have clinical activity in blocking the VEGF pathway: the use of small molecule TK inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ) to block the intracellular domain of the VEGF receptor, monoclonal antibodies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , that bind to circulating VEGF and prevent its activating the VEGF receptor (VEGFR), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , a fusion molecule consisting of portions of the binding domains of several VEGFRs attached to the Fc portion of human IgG1 that binds to and inhibits VEGF binding to all classes of VEGFR as well as placenta growth factor (PlGF) binding to VEGFR1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several complications associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , three of which have the potential to affect the lungs: hemorrhage, tracheoesophageal (TE) fistula and thromboembolic disease. Although bevacizumab clearly increases the risk for arterial thrombosis, whether it also increases the risk of venous thromboembolic disease is uncertain. These topics are covered in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link&amp;anchor=H1651227415#H1651227415\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Pulmonary hemorrhage and cavitation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link&amp;anchor=H91044871#H91044871\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Tracheoesophageal fistula'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link&amp;anchor=H291526412#H291526412\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Arterial and venous thromboembolism'",
"    </a>",
"    .) Whether the presence of tumor cavitation (which is more common with squamous cell cancers) implies a higher risk of hemorrhage is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sunitinib and sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor cavitation and bleeding complications have been observed rarely with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    for NSCLC. However, pulmonary hemorrhage has not been described in patients receiving either drug for other malignancies, and neither agent is approved for treatment of lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dyspnea and cough have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    . In a review of the drug approval report for treatment of gastrointestinal stromal tumors (GISTs) or advanced renal cell cancer, severe (grade 3 or 4) dyspnea was seen in 19 percent of patients and cough in 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/71\">",
"     71",
"    </a>",
"    ]. There are no reports of sunitinib-induced pneumonitis. However, postmarketing experience has revealed cases of pulmonary embolism, some fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare cases of pulmonary toxicity with dyspnea, cough, and fever have been reported in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    . In a postmarketing surveillance study of patients receiving sorafenib for advanced renal cell carcinoma or unresectable hepatocellular carcinoma, pulmonary toxicity was very uncommon (0.44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/73\">",
"     73",
"    </a>",
"    ]. However, among those affected, diffuse pulmonary opacities were noted on chest imaging in approximately 50 percent, and the case fatality rate was 41 percent (25 of 62). Thus for suspected pulmonary toxicity in patients receiving sorafenib, early cessation of the drug is the most prudent approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OTHER MONOCLONAL ANTIBODIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Agents targeting the EGFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    (Erbitux) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    (Vectibix) are monoclonal antibodies that directly target the EGFR; they are both used for treatment of advanced colorectal cancer, and cetuximab is also of benefit for head and neck cancer.",
"   </p>",
"   <p>",
"    Severe acute infusion reactions, which may include bronchospasm, have been described in 2.5 to over 20 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , depending on the geographic area. Infusion reactions are much less frequent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    (4 percent overall, 1 percent severe). This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H48#H48\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Cetuximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H52#H52\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Panitumumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the anti-EGFR small molecule TK inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , pulmonary parenchymal toxicity appears to be rare with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and limited to isolated case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Initial reports suggested that pulmonary toxicity was also rare with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    ; pulmonary fibrosis developed in 2 of 1467 patients enrolled in clinical trials (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/76\">",
"     76",
"    </a>",
"    ]. However, an increased number of cases of fatal interstitial lung disease and pulmonary fibrosis have been reported to the FDA during postmarketing surveillance, prompting a warning about this issue in December 2011. Panitumumab is typically discontinued if interstitial lung disease develops, as pulmonary disease associated with panitumumab has been fatal in some patients. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Anti-EGFR agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    (Herceptin&reg;) is a humanized monoclonal antibody that binds to a specific epitope of the HER2 protein on the breast cancer cell surface. Between 20 and 40 percent of women have an infusion reaction during the first treatment with trastuzumab; symptoms may include dyspnea, fever, chills, nausea, headache, and abdominal pain. Most reactions are mild; only about 0.3 percent of patients have serious infusion reactions with features of anaphylaxis (bronchospasm, hypotension, angioedema). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H31#H31\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Trastuzumab and other HER2-targeted therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolated cases of acute respiratory distress syndrome (ARDS), subacute interstitial pneumonia, and organizing pneumonia have been reported in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    (incidence less than 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/77-81\">",
"     77-81",
"    </a>",
"    ]. Although infrequent, pulmonary toxicity due to trastuzumab may be life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Discontinuation of trastuzumab is advised in any patient who develops pneumonia or ARDS during treatment. Improvement following treatment with glucocorticoids has been reported; however, the role of glucocorticoid therapy in trastuzumab-induced pulmonary toxicity has not been formally studied [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/77,78,80\">",
"     77,78,80",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    should be used with caution in patients with preexisting lung disease or with widespread metastatic disease to the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351180547\">",
"    <span class=\"h3\">",
"     Trastuzumab emtansine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/16/11527?source=see_link\">",
"     Trastuzumab emtansine",
"    </a>",
"    (T-DM1) is an antibody-drug conjugate that incorporates",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    with the cytotoxic microtubule inhibitor DM1. It is approved for advanced breast cancer in patients previously exposed to trastuzumab and taxanes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H720673240#H720673240\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'Ado-trastuzumab emtansine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute pneumonitis (including severe, life-threatening cases) is rarely reported with T-DM1. In clinical trials, the incidence has been low overall (0.8 to 1.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/82\">",
"     82",
"    </a>",
"    ]. Signs, symptoms, and clinical findings included dyspnea, cough, fatigue and pulmonary opacities. Patients with preexisting dyspnea because of advanced malignancy or other comorbidity may be at increased risk. Information is not available on reversibility with or without glucocorticoids. Treatment with T-DM1 should be discontinued in any patient who develops pulmonary toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a B cell depleting anti-CD20 monoclonal antibody that contains both mouse and human components. Although it has been primarily used for the treatment of CD20-positive non-Hodgkin lymphoma, indications in rheumatology and solid organ transplant have increased the number of patients exposed to this agent.",
"   </p>",
"   <p>",
"    One of the most predictable side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is an infusion reaction that occurs within the initial 30 to 120 minutes of the first exposure in over 50 percent of patients. The most common symptoms and signs are headache, fever, chills, sweats, skin rash, dyspnea, mild hypotension, nausea, rhinitis, urticaria, pruritus, asthenia, and a sensation of tongue and throat swelling (angioedema); bronchospasm is present in fewer than 10 percent of cases. Infusion reactions are markedly less common with subsequent infusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary parenchymal toxicity is uncommonly reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. The incidence in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for lymphoma has been addressed in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 107 patients, nine (8 percent) developed interstitial pneumonia (ILD) while receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      -containing chemotherapy for non-Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/84\">",
"       84",
"      </a>",
"      ]. The median number of cycles of rituximab prior to presentation was two. Clinical symptoms included high fever, with or without dyspnea or non-productive cough. Treatment consisted of high-dose glucocorticoids with a slow taper and empiric antibiotics against atypical pathogens. Eight patients responded to glucocorticoids, while one died of secondary infection. Rechallenge resulted in recurrence of interstitial pneumonitis in two of four patients and is generally not recommended.",
"     </li>",
"     <li>",
"      In a randomized trial, ILD was reported in a higher percentage of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus CHOP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) as compared to CHOP alone (14 versus 0 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/85\">",
"       85",
"      </a>",
"      ]. However, some of these cases represented opportunistic infection with Pneumocystis jirovecii or a fungal infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discontinuation of the drug and prompt initiation of glucocorticoids typically leads to resolution of pulmonary manifestations; however, fatalities are reported. In a systematic review of the published literature, nine of 31 patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -associated lung injury died (29 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Particularly if glucocorticoid therapy is being considered for patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -associated ILD, it is mandatory to exclude an infectious etiology with appropriate cultures, often including BAL. Empiric antimicrobial therapy directed at likely pathogens is often indicated while diagnostic procedures and cultures are performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RAPAMYCIN AND ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonitis is a known side effect of inhibitors of mTOR (the mammalian target of rapamycin). In a meta-analysis of trials in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    were used to treat solid malignancies (2233 patients), the incidences of high-grade and overall pulmonary toxicity were 2 and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/87\">",
"     87",
"    </a>",
"    ]. The presentation varies from asymptomatic radiographic abnormalities to significant respiratory impairment; most cases resolve with drug discontinuation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link&amp;anchor=H24#H24\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\", section on 'Respiratory system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    are macrolide mTOR inhibitors that have antiproliferative properties; they are active in the treatment of advanced renal cell cancer (RCC) and are under study for advanced neuroendocrine tumors. Although infrequent, potentially fatal ILD is reported in patients receiving these agents, as described in the following sections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/88-91\">",
"     88-91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Temsirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     Temsirolimus",
"    </a>",
"    has been associated with pneumonitis in 0.5 to 5 percent of patients with cancer who were enrolled in clinical studies; some had severe toxicity, including rare fatalities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/90,92-94\">",
"     90,92-94",
"    </a>",
"    ]. Symptoms and signs suspicious for pneumonitis include pleural effusion, hypoxia, cough, dyspnea, and malaise.",
"   </p>",
"   <p>",
"    Low-grade pneumonitis may be more common than severe pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/95\">",
"     95",
"    </a>",
"    ]. Radiographic findings consistent with drug-induced pneumonitis were detected in 36 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    for advanced neuroendocrine tumors and endometrial carcinoma in an independent review of serial radiographic studies performed for response assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/96\">",
"     96",
"    </a>",
"    ]. Radiographic findings included ground glass opacity or consolidation. One-half were asymptomatic. Drug treatment was continued in some cases without worsening of the pneumonitis.",
"   </p>",
"   <p>",
"    However, others have shown a high rate of recurrent pneumonitis after rechallenge. In a phase II trial, four (2 percent) of 208 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    developed ILD of varying severity, including grades 3 and 4 (",
"    <a class=\"graphic graphic_table graphicRef61493 \" href=\"UTD.htm?18/50/19243\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/91\">",
"     91",
"    </a>",
"    ]. Patients were managed with antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temsirolimus dose reduction or discontinuation. Of the four patients who were retreated after symptom resolution, two experienced recurrent pneumonitis.",
"   </p>",
"   <p>",
"    Monitoring and management guidelines are not yet established for patients who develop radiographic changes while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    , with or without symptoms indicative of ILD. A suggested approach has been proposed based upon an analysis of experience in a phase III trial (",
"    <a class=\"graphic graphic_table graphicRef69423 \" href=\"UTD.htm?20/55/21372\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/94\">",
"     94",
"    </a>",
"    ]. However, only four patients in this trial developed pneumonitis of any severity while receiving temsirolimus, only one of which was severe.",
"   </p>",
"   <p>",
"    In our view and that of others, clinical suspicion of symptomatic drug induced lung toxicity generally justifies treatment discontinuation and consideration of an alternative agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. There is no published experience with glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    is an orally active mTOR inhibitor; clinical pneumonitis has been reported in 8 to 14 percent of patients receiving systemic treatment with everolimus; as with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    , there appears to be a higher incidence of low-grade than high-grade pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/95,97-101\">",
"     95,97-101",
"    </a>",
"    ]. The following represents the range of findings: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a placebo-controlled randomized trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      for advanced renal cell carcinoma, clinical pneumonitis was suspected in 37 (14 percent) of the 274 patients who received everolimus [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/97\">",
"       97",
"      </a>",
"      ]. Ten had severe (grade 3) pneumonitis (",
"      <a class=\"graphic graphic_table graphicRef61493 \" href=\"UTD.htm?18/50/19243\">",
"       table 1",
"      </a>",
"      ), five of whom had radiologic evidence of pneumonitis before drug administration.",
"     </li>",
"     <li>",
"      In another phase III trial, pneumonitis of any grade was detected in 22 patients (8 percent) receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      for advanced renal cell cancer, and it was grade 3 severity (",
"      <a class=\"graphic graphic_table graphicRef61493 \" href=\"UTD.htm?18/50/19243\">",
"       table 1",
"      </a>",
"      ) in eight [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, in a randomized trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      for treatment of advanced carcinoid in 429 patients, pneumonitis of any grade was detected in 18 patients who received combined therapy (8 percent) versus none in the control group; pneumonitis was serious (life-threatening, requiring hospitalization or intervention, causing disability or permanent damage) in three patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 64 patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      for NSCLC, 24 (38 percent) had newly occurring or worsening radiographic findings consistent with pneumonitis during therapy and 21 developed ILD within three months of starting treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/98\">",
"       98",
"      </a>",
"      ]. In most of the patients, pneumonitis remained at the same or lower grade without discontinuation of therapy.",
"     </li>",
"     <li>",
"      Pneumonitis has also been reported following the placement of an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      -eluting coronary artery stent, but the frequency with which this occurs is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Baseline ILD appears to be a risk factor for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    -associated pneumonitis; in one series, it was present in 29 versus 8 percent of patients who did and did not develop pneumonitis during treatment, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/97\">",
"     97",
"    </a>",
"    ]. Of the six cases that were graded as severe (grade 3 or 4, (",
"    <a class=\"graphic graphic_table graphicRef61493 \" href=\"UTD.htm?18/50/19243\">",
"     table 1",
"    </a>",
"    )), four had ILD at baseline; two were fatal.",
"   </p>",
"   <p>",
"    The most common symptoms are dyspnea, cough, fatigue, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. The most common radiographic features are focal areas of consolidation at the lung bases or ground glass opacities, but some patients manifest diffuse ground glass or consolidative opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings on BAL were described in a report of seven patients who developed interstitial lung disease while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    for advanced renal cell cancer, four patients underwent bronchoalveolar lavage (BAL), all of whom had BAL lymphocytosis (43 to 82 percent) and two had an increased eosinophil count (10 and 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/101\">",
"     101",
"    </a>",
"    ]. Transbronchial lung biopsies obtained from three patients revealed interstitial lymphocytic inflammation and mild septal thickening of alveolar walls; some alveoli had fibrinous exudates.",
"   </p>",
"   <p>",
"    The clinical course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    -related ILD has been described in two reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the placebo-controlled randomized trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      for advanced renal cell carcinoma, in which clinical pneumonitis was suspected in 37, glucocorticoid therapy was initiated in 16 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/97\">",
"       97",
"      </a>",
"      ]. Twenty of the 37 cases (54 percent) were reversible within the follow-up period. Of the 10 patients with grade 3 pneumonitis, six received glucocorticoids. One of the three patients who continued everolimus had resolution, one improved and one died, thought due to disease progression rather than drug toxicity. Of the seven who discontinued treatment, all had complete resolution. The contribution of glucocorticoid treatment to recovery was unclear.",
"     </li>",
"     <li>",
"      In one of the retrospective series described above, of seven patients who developed ILD during treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      , two cases had mild ILD, the drug was continued successfully, but in the four cases of grade 3 ILD, drug was discontinued, and glucocorticoids instituted with radiographic and symptomatic clearing within two months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/101\">",
"       101",
"      </a>",
"      ]. There were two few patients to determine the relative effects of drug interruption or glucocorticoid therapy on pneumonitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monitoring and management guidelines have been suggested for patients who develop symptoms or radiographic changes while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    based on the grade of pneumonitis (",
"    <a class=\"graphic graphic_table graphicRef61493 \" href=\"UTD.htm?18/50/19243\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/97,104\">",
"     97,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 1 pneumonitis: observe the patient closely (eg, repeat chest",
"      <span class=\"nowrap\">",
"       X-ray/CT",
"      </span>",
"      scan every two cycles) while continuing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      therapy.",
"     </li>",
"     <li>",
"      Grade 2 pneumonitis: reduce",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      dose of 5 mg daily until improvement to grade 1 or less and discontinue everolimus if improvement to grade 1 or less does not occur within three weeks. Glucocorticoids are administered only if cough is troublesome. Obtain chest CT scan and pulmonary function tests each cycle.",
"     </li>",
"     <li>",
"      Grade 3 pneumonitis: prescribe systemic glucocorticoids after infection is excluded; after improvement, taper glucocorticoids as tolerated.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       Everolimus",
"      </a>",
"      is interrupted until improvement of pneumonitis to grade 1 or less. Everolimus may be resumed in two weeks at a reduced dose of 5 mg daily if clinical benefit is evident. Monitor chest CT and pulmonary function tests each subsequent cycle.",
"     </li>",
"     <li>",
"      Grade 4 pneumonitis: prescribe systemic glucocorticoids after infection is excluded; after improvement, taper glucocorticoids as tolerated. Permanently discontinue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary toxicity associated with molecularly targeted therapy is relatively frequent and the diagnosis should be entertained once careful investigations have excluded alternative explanations, including opportunistic infections, radiation-induced lung injury, or metastatic involvement of the lungs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H15#H15\">",
"       \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are no clearly defined criteria for drug-induced lung disease. Because signs and symptoms are generally non-specific, the diagnosis usually remains one of exclusion. A presumptive diagnosis can be made when pneumonitis develops shortly after the initiation of treatment, an alternative explanation for the respiratory compromise is lacking, and the pneumonitis resolves soon after withdrawal of the presumed agent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      after glucocorticoid treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?28/49/29466/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients who develop lung toxicity during treatment with a molecularly targeted agent, the decision to continue treatment, interrupt therapy, or switch to an alternative agent must be carefully considered based upon the clinical circumstances, and the nature and severity of the pulmonary toxicity. In general, suspicion of significant lung toxicity justifies discontinuation of the drug.",
"     </li>",
"     <li>",
"      No specific treatment has proven effective besides discontinuation of the suspected offending agent. The use of glucocorticoids is often recommended in the more severe cases, but based upon anecdotal reports. Although the risk of opportunistic infection may be slightly increased, a short course of high-dose glucocorticoids is often considered appropriate in these situations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"       \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/1\">",
"      Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004; 140:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/2\">",
"      Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266:2847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/3\">",
"      Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleve Clin J Med 2001; 68:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/4\">",
"      Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008; 177:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/5\">",
"      Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004; 45:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/6\">",
"      Haidl ID, Huber G, Eichmann K. An ADAM family member with expression in thymic epithelial cells and related tissues. Gene 2002; 283:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/7\">",
"      Miettinen PJ, Warburton D, Bu D, et al. Impaired lung branching morphogenesis in the absence of functional EGF receptor. Dev Biol 1997; 186:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/8\">",
"      Hardie WD, Prows DR, Leikauf GD, Korfhagen TR. Attenuation of acute lung injury in transgenic mice expressing human transforming growth factor-alpha. Am J Physiol 1999; 277:L1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/9\">",
"      Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003; 8:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/10\">",
"      Endo M, Johkoh T, Kimura K, Yamamoto N. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 2006; 52:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/11\">",
"      Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003; 22:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/12\">",
"      Ohyanagi F, Ando Y, Nagashima F, et al. Acute gefitinib-induced pneumonitis. Int J Clin Oncol 2004; 9:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/13\">",
"      Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/14\">",
"      Leidner RS, Fu P, Clifford B, et al. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 2009; 27:5620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/15\">",
"      Cleverley JR, Screaton NJ, Hiorns MP, et al. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002; 57:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/16\">",
"      Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006; 24:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/17\">",
"      Inomata S, Takahashi H, Nagata M, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 2004; 15:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/18\">",
"      Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/19\">",
"      Hotta K, Kiura K, Tabata M, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005; 11:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/20\">",
"      Lim KH, Chang YH. Interstitial lung disease and gefitinib. N Engl J Med 2010; 363:1579; author reply 1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/21\">",
"      Fukui T, Otani S, Hataishi R, et al. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol 2010; 65:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/22\">",
"      Chang SC, Chang CY, Chen CY, Yu CJ. Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. J Thorac Oncol 2010; 5:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/23\">",
"      Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:5080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/24\">",
"      Spigel DR, Lin M, O'Neill V, Hainsworth JD. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer 2008; 112:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/25\">",
"      Cohen MH, Johnson JR, Chen YF, et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005; 10:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/26\">",
"      Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010; 5:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/27\">",
"      Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/28\">",
"      Liu V, White DA, Zakowski MF, et al. Pulmonary toxicity associated with erlotinib. Chest 2007; 132:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/29\">",
"      Makris D, Scherpereel A, Copin MC, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007; 7:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/30\">",
"      Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/31\">",
"      Yoneda KY, Shelton DK, Beckett LA, Gandara DR. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2007; 2:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/32\">",
"      Lind JS, Smit EF, Gr&uuml;nberg K, et al. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. J Thorac Oncol 2008; 3:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/33\">",
"      Kubota K, Nishiwaki Y, Tamura T, et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008; 3:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/34\">",
"      Tammaro KA, Baldwin PD, Lundberg AS. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). J Oncol Pharm Pract 2005; 11:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/35\">",
"      Capri G, Chang J, Chen SC, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010; 21:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/36\">",
"      Goldsby R, Pulsipher M, Adams R, et al. Unexpected pleural effusions in 3 pediatric patients treated with STI-571. J Pediatr Hematol Oncol 2002; 24:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/37\">",
"      Ishii Y, Shoji N, Kimura Y, Ohyashiki K. Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Intern Med 2006; 45:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/38\">",
"      Breccia M, D'Elia GM, D'Andrea M, et al. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol 2005; 74:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/39\">",
"      Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003; 21:3171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/40\">",
"      Yokoyama T, Miyazawa K, Kurakawa E, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004; 18:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/41\">",
"      Lin JT, Yeh KT, Fang HY, Chang CS. Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate. Leuk Lymphoma 2006; 47:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/42\">",
"      Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003; 78:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/43\">",
"      Bergeron A, Bergot E, Vilela G, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol 2002; 20:4271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/44\">",
"      Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006; 20:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/45\">",
"      Rajda J, Phatak PD. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Am J Hematol 2005; 79:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/46\">",
"      Wagner U, Staats P, Moll R, et al. Imatinib-associated pulmonary alveolar proteinosis. Am J Med 2003; 115:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/47\">",
"      Yamasawa H, Sugiyama Y, Bando M, Ohno S. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration 2008; 75:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/48\">",
"      Grimison P, Goldstein D, Schneeweiss J, Murray N. Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms. Intern Med J 2005; 35:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/49\">",
"      Seki N, Ito A, Watanabe K, et al. Irreversible imatinib-induced pneumonitis following long-term imatinib administration. Intern Med 2007; 46:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/50\">",
"      Izumiyama N, Noguchi K, Takahashi H, et al. [Successful reintroduction of mesylate imatinib after pneumonitis in two patients with gastrointestinal stromal tumor (GIST)]. Nihon Kokyuki Gakkai Zasshi 2009; 47:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/51\">",
"      Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med 2010; 16:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/52\">",
"      Goldblatt M, Huggins JT, Doelken P, et al. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci 2009; 338:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/53\">",
"      Latagliata R, Breccia M, Fava C, et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/54\">",
"      Masiello D, Gorospe G 3rd, Yang AS. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009; 2:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/55\">",
"      Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/56\">",
"      Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/57\">",
"      Quint&aacute;s-Cardama A, Kantarjian H, O'brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25:3908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/58\">",
"      Kathula SK. Dasatinib in chronic myelogenous leukemia. N Engl J Med 2006; 355:1062; author reply 1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/59\">",
"      Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012; 36:e4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/60\">",
"      Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011; 38:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/61\">",
"      Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009; 43:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/62\">",
"      Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009; 33:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/63\">",
"      Montani D, Bergot E, G&uuml;nther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/64\">",
"      Force T. Double-edged sword of the new cancer therapeutics. Circulation 2012; 125:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/65\">",
"      Bergeron A, R&eacute;a D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007; 176:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/66\">",
"      Radaelli F, Bramanti S, Fantini NN, et al. Dasatinib-related alveolar pneumonia responsive to corticosteroids. Leuk Lymphoma 2006; 47:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/67\">",
"      Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/68\">",
"      Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/69\">",
"      Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012; 119:3403.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/71\">",
"      Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13:1367.",
"     </a>",
"    </li>",
"    <li>",
"     US FDA-approved manufacturer's product information available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c#S5.6 (Accessed on August 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/73\">",
"      Horiuchi-Yamamoto Y, Gemma A, Taniguchi H, et al. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. Int J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/74\">",
"      Chua W, Peters M, Loneragan R, Clarke S. Cetuximab-associated pulmonary toxicity. Clin Colorectal Cancer 2009; 8:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/75\">",
"      Neyns B, Aerts M, Van Nieuwenhove Y, et al. Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases. Anticancer Res 2008; 28:2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/76\">",
"      Giusti RM, Shastri K, Pilaro AM, et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008; 14:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/77\">",
"      Vahid B, Mehrotra A. Trastuzumab (Herceptin)-associated lung injury. Respirology 2006; 11:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/78\">",
"      Radzikowska E, Szczepulska E, Chabowski M, Bestry I. Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Eur Respir J 2003; 21:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/79\">",
"      Bettini AC, Tondini C, Poletti P, et al. A case of interstitial pneumonitis associated with Guillain-Barr&eacute; syndrome during administration of adjuvant trastuzumab. Tumori 2008; 94:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/80\">",
"      Pepels MJ, Boomars KA, van Kimmenade R, Hupperets PS. Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Res Treat 2009; 113:609.",
"     </a>",
"    </li>",
"    <li>",
"     Herceptin (trastuzumab for injection). FDA approved package insert. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on December 02, 2010).",
"    </li>",
"    <li>",
"     FDA-approved prescribing information for trastuzumab emtansine available online at file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf?et_cid=31141095&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f125427lbl.pdf (Accessed on February 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/83\">",
"      Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/84\">",
"      Liu X, Hong XN, Gu YJ, et al. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2008; 49:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/85\">",
"      Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 2008; 87:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/86\">",
"      Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol 2009; 44:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/87\">",
"      Iacovelli R, Palazzo A, Mezi S, et al. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 2012; 51:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/88\">",
"      Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/89\">",
"      Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/90\">",
"      Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/91\">",
"      Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/92\">",
"      Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/93\">",
"      Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/94\">",
"      Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008; 19:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/95\">",
"      Dabydeen DA, Jagannathan JP, Ramaiya N, et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012; 48:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/96\">",
"      Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006; 17:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/97\">",
"      White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/98\">",
"      White DA, Schwartz LH, Dimitrijevic S, et al. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol 2009; 4:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/99\">",
"      Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27:4536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/100\">",
"      Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009; 20:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/101\">",
"      Mizuno R, Asano K, Mikami S, et al. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2012; 42:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/102\">",
"      Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/103\">",
"      Sakamoto S, Kikuchi N, Ichikawa A, et al. Everolimus-induced Pneumonitis after Drug-eluting Stent Implantation: A Case Report. Cardiovasc Intervent Radiol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/104\">",
"      Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/49/29466/abstract/105\">",
"      Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008; 133:528.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4336 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-D2AB0E8FD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29466=[""].join("\n");
var outline_f28_49_29466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SMALL MOLECULE TYROSINE KINASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anti-EGFR agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Gefitinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Erlotinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lapatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bcr-Abl tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Imatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dasatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16655010\">",
"      - Nilotinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9315266\">",
"      - Bosutinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11220652\">",
"      Crizotinib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      AGENTS TARGETING VEGF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sunitinib and sorafenib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OTHER MONOCLONAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Agents targeting the EGFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H351180547\">",
"      - Trastuzumab emtansine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RAPAMYCIN AND ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Temsirolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Everolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4336|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/50/19243\" title=\"table 1\">",
"      NCI CTCAE pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/55/21372\" title=\"table 2\">",
"      Pneum ILD temsirolimus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17050?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=related_link\">",
"      Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_49_29467="Causes of endolymphatic hydrops";
var content_f28_49_29467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of endolymphatic hydrops*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Acoustic trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune inner ear disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic otitis media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cogan's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital deafness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endolymphatic sac tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fenestration of the otic capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Labyrinthine concussion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Letterer-Siwe disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemic infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mondini dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Otosclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paget's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serous labyrinthitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical trauma to inner ear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Temporal bone/head trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral labyrinthitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Endolymphatic hydrops determined at autopsy.",
"    </div>",
"    <div class=\"reference\">",
"     <br>",
"      Adapted from Jackler, RK, Brackmann, DE, Eds, Neurotology, Mosby Year Book Inc, Missouri 1994, p. 635.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29467=[""].join("\n");
var outline_f28_49_29467=null;
var title_f28_49_29468="Healthy People 2020 nutrition objectives";
var content_f28_49_29468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Healthy People 2020: Selected nutrition objectives",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Weight status",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        2020 targets*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce the proportion of children 2 to 5 years who are obese",
"       </td>",
"       <td>",
"        &nbsp;9.6 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce the proportion of&nbsp;children 6 to 11 years&nbsp;who are obese",
"       </td>",
"       <td>",
"        &nbsp;15.7 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce the proportion of adolescents who are obese",
"       </td>",
"       <td>",
"        &nbsp;16.1 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce the proportion of adults who are obese",
"       </td>",
"       <td>",
"        &nbsp;30.6 percent&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Food and nutrient consumption (2 years and older)",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        2020 targets",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increase the contribution of fruits to the diet&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        0.9 cup-equivalents per 1000 calories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increase the contribution of vegetables to the diet, with at least one-third of these servings being dark green or deep yellow vegetables",
"       </td>",
"       <td>",
"        1.1 cup-equivalents total vegetables per 1000 calories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increase the contribution of&nbsp;whole grains&nbsp;to the diet&nbsp;",
"       </td>",
"       <td>",
"        0.6 ounce-equivalents of whole grains per 1000 calories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce the consumption of calories from solid fats and saturated fat",
"       </td>",
"       <td>",
"        <p>",
"         Solid fats no more than 16.7 percent of caloric intake",
"        </p>",
"        <p>",
"         Saturated fats no more than 9.5 percent of caloric intake",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce the consumption of calories from added sugars",
"       </td>",
"       <td>",
"        Added sugars no more than 10.8 percent of caloric intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increase consumption of calcium",
"       </td>",
"       <td>",
"        1300 milligrams daily&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Target selected to represent a 10 percent improvement over baseline. In children and adolescents, obesity is defined as &ge;95th percentile of body mass index (BMI) for age and gender. In adults, obesity is defined as&nbsp;BMI &ge;30.",
"     <br>",
"      &bull; Target selected to represent an achievable shift in the population intake, based on past trends and consideration of&nbsp;the target's&nbsp;applicability to subpopulations.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From US DHHS. Healthy People 2020: Nutrition and weight status objectives. Available at:",
"     <a href=\"file://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=29\">",
"      file://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=29",
"     </a>",
"     (accessed 3/27/2012)",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29468=[""].join("\n");
var outline_f28_49_29468=null;
var title_f28_49_29469="Persistent white coat HTN";
var content_f28_49_29469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Persistent white-coat hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 246px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Measurement of systolic blood pressure by nurses at two screening visits (S1 and S2) and during five-year follow-up in patients from the Medical Research Council Mild Hypertension trial. The measurements made by a doctor are denoted by D; all other measurements were made by nurses. A white-coat effect, leading to higher measurements by doctors, is present throughout the study, being most prominent at the entry examination (E).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Millar JA, Isles CG, Lever AF. J Hypertens 1995; 13:175.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29469=[""].join("\n");
var outline_f28_49_29469=null;
var title_f28_49_29470="Contents: Plasma cell disorders";
var content_f28_49_29470=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?39/57/40861\">",
"       Hematology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Plasma cell disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Plasma cell disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Monoclonal gammopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/60/4041\">",
"           Clinical course and management of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15290\">",
"           Diagnosis of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/58/10154\">",
"           Recognition of monoclonal proteins",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple myeloma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/28/36296\">",
"           Allogeneic hematopoietic cell transplantation in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/47/31482\">",
"           Autologous hematopoietic cell transplantation in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/13/35034\">",
"           Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/29/8666\">",
"           Determination of initial therapy in patients with multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/17/16662\">",
"           Diagnosis and management of solitary extramedullary plasmacytoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44535\">",
"           Diagnosis and management of solitary plasmacytoma of bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/50/31526\">",
"           Evaluating response to treatment of multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/52/32584\">",
"           Initial chemotherapy for patients with high risk multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/1/28698\">",
"           Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/54/18282\">",
"           Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/20/27977\">",
"           Pathobiology of multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/1/22551\">",
"           Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/42/16039\">",
"           Plasma cell leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/58/10154\">",
"           Recognition of monoclonal proteins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10618\">",
"           Staging and prognostic studies in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/27/30137\">",
"           The use of bisphosphonates in patients with multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30409\">",
"           Treatment of kidney disease in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/15/37114\">",
"           Treatment of relapsed or refractory multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/13/23769\">",
"           Treatment of the complications of multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/48/27400\">",
"           Types of renal disease in multiple myeloma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34040\">",
"           Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/14/35049\">",
"           POEMS syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/12/12484\">",
"           Plasma exchange in the hyperviscosity syndrome due to immunoglobulins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/11/12470\">",
"           The heavy chain diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/52/36682\">",
"           Treatment of the mixed cryoglobulinemia syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Primary amyloidosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/31/1530\">",
"           An overview of amyloidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23722\">",
"           Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/15/7418\">",
"           Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/63/12280\">",
"           Gastrointestinal amyloidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/62/35815\">",
"           Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/9/35994\">",
"           Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/29/13784\">",
"           Renal amyloidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/25/23958\">",
"           Treatment of amyloid cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Waldenstrom macroglobulinemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/47/762\">",
"           Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr������m macroglobulinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/47/37626\">",
"           Treatment and prognosis of Waldenstr������m macroglobulinemia",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-39D08A5F56-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f28_49_29470=[""].join("\n");
var outline_f28_49_29470=null;
var title_f28_49_29471="Intest transplant adult";
var content_f28_49_29471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Indication for intestinal transplantation in adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 326px; background-image: url(data:image/gif;base64,R0lGODlhJgJGAfcAAIxqRHhPIwAka6CgoOpqalgsWPDw8FpypEBAQPXSy5CQkO/NquOfW25ublBQUHyT7XBwcNyELAAAADYbNpsAAKMAABFMUcR1LgAs3DAwMAZ2U2ybhF9fX1mLaABQNeDg4KNiITodOu+KipvQ0ACKq7/K9s6vl05zdwB2koxsKPC/vwAshDY5fdDX7XZeRfro36nEsdru8qhlIrCwsL2NXABYmSAgIJlcH4VwhQCEWICAgAAiZCxXWOQ9PfPg07C71jha4QBSZXFlVREsMwBrexw0rx9qWPD09q1oI9wAABAQEHABAtS9qAY2Q5RZHtDQ0Prz8Zqr8Ji4pWc2UgUoe5qoynFRcRxjMRZSKHZoKc6EhDp7i8CzwABCu4mqlMDAwDRXJwAbhauWq9ra2gCBoEh9WnZZOllGVLwAAMzIxCpMlHeKtEkmSYqKihqRaXZSLbZtJMbWyqtkPCiAlY4PLlItM1Ry5xpcLRiBmhZOJ7WntS9pPNLj2zQAAP///4CRwUdZJwARRO3t7UkdV0plLKwyMr10JzA6kah0KlIxWHoSNgFDUby+tAgvyw07Ht3W3Z5fILaYeEo6WFc2FbTQwhdA3+Hr5hRZQcFkZCcqLQpAZHJHIUwAANHf2lUPLmY6LQU2c7hwN9F+LBszNeDk7g6Fop2MnSISJQATMSMZTSRQcdDa1mVnZRMAAN0QECA6bs4BBQ9DNc7HzhdTKTkkDYlSIsDJ32VJK31hfwMlGQAjsBIJEhhYKwMTDX9LJRZRKH1LGWAYSrcHFCIkbxdQJ72nj0Cjgrrf6D1HV7/g1dXK1S+bd+PVx0FboOjk6EirwxpfM94PDz09fSQ2n+AfH9+PQC+fuktBaPDq4xQ7h3jB0mZhJw+RsAFFLmRJQIBfKR+YtWI5YkEhP+u7iqC+tAQGCRWEn6VXRRAxcQeGpYTDrq+99N/k+hkPBlE5UQBgQqm/r5xnJhQriAAnc2xUPIRKRqhtMZp8WwMxWo9VIK99SkITOoCIipJ9kiRtdzU3OCH5BAAAAAAALAAAAAAmAkYBAAj/AP0IHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiBMrXsy4sePHkCNLnkx58IcvTwQa+PLFzxMEAyqLHo1VhwQlAjlIkODng47OpBVy5vyB4QAEmSl+Dh2790XTEgYYWM3adecnHBA4CG1AAQIECkYTl6CDoWnYE4373k7RtI0MCmys//bzhfoHCRl0cHDgB4EECBBQj3YPe4YDBBw6f0nO4YlpBcnNINAX90FgAHk62OeAATqA1tpr5N0HHXcUKvTfaQqMV54OT0hgAwQKGNAhBwLVNp8EnQ0ggQM6sFheegjoYJoS7knwwQwrQrCiHzNmcFoGSti4IY8cNBhchUgWdJ2Pw7E25AwIBJnBkL3R50eG6YXmgI0lXueHjgRSp4N4PKLohwQIlMkZdX4054CP1SUp53UfZKYhdfvN8IUSqPE5wwwZkGYljzVC4B5BXl7nnowyqnlmmtcNCaQCGcYpJ5JeCnSnDh/4iF5mT2yJ5mhf+KjABwpA8IWKDmSYH6NmXv+XoQNfzECil6NGyqaHX+ho6aXABkvQdAmKt+KBY542Q6KxGsserpCiOKSKaLIp7LXYZqvtttx26+234IYr7rjklmsuYA6YeK6D54bbYLs6ZHBgu+GCZ26HudEL7hNKqBuuATZEp6+48ZLrAHsDj5seTrM1zOjDEEOsZ8NfzIvVADZYnPC+EuRb0mWrypjcc0FOZ/LJKKescgbPIQCBjANw5rFR/GK3sbuBenTZADoYWqPKQAct9NAq2/AczJj9ZMDCN5PLNEW1KqAeAsYSbfXVWGe92tGvzSyToU2Xi69Dmw3QBgTrsdIAB+Vo7fbbcAtNY5EzeJ3SDP2GXW7BCD3/McAAEBzcwOCEEy5q3IgnrriHMcaM0gdKCKh3uU9/MECqDnBQ+Oac/7z456BrbXSCdm/k8uT3SoC55py3zjkE/4Qu++xZu6yAzRjFqzHq3RowQxusvKmE68S7ngntyCc/dAYQDFC6Q3s+z3uwXwDoQOHx/VP89oVXrfz34Jsc4wy7LwSwwNNja3mLrEDQOgeZcC8/KyWHb//9NnDgPEMKIJx+sE8AEOvkR8Dtse1+CESgElolvf9dyj8cGGABJ1i8AybwgvZboAIa6MDeQFCCFAwh8Q6HwRKCL38D8FcHTQKypLXkdD2xXOZESEP5ec6EOFQe83C3wpAAZzU5O8io/0IyxIZkCiU8u14NCdeGGTBCAYNTwJ/c14A2tIGCnsqhFr+3HBX2kCOm0cHSzMQg5QhIRTbgFM9QdRkJCUwHl8PPgZCjnNDA0TlxGhWBnvPGOHLAAB9wj/5Y2KIlbi4NfhDEGGYAgTb4IQ2CeAJ8oAA4Ch5vi5jUIQQ4+MWIhBFgXAJSvDqmIxp95jQoUo+RQgNE8XDgPOlZz5mUEDjVPYpIqzwTelz5BPEwjyQzYAUHqGjIBjTPM4SDgICU6YcGfMEZNKxfJqc5OyVwQHKd/M10QtOhGKmmOkN0z7zcBKdbDgc3HgLRgUZ1TnP2r5zszJWZQmKAAThAbcXcXGbG4P+HI0BxmV+AQnUGkIYxpAE+BaQfNRdKO2sKJ5vdkQAHghSd8sRIRp0JJ2sEMqlK3fKWUJLSR0c1qo7uKk23PGJHPsCP6xEzn4Tj558S2QAdHMEZR/hCQb/gz5xOEG1tY6hQZbec8kHUQnhaTWb4FDMFsNIGXwjkRs8EVV+NFAF52hNq0LMfW5K0qifVVLQgxJEPcKAJQ1AiTPV5pQYIhHAKaEN1FDCGMTSgriG04FD3+rmiHtU6bNKRvEK1GhsICDinHAi1FnXVTgHRTnx6j1j9sNiw3vID4vEfRvbTBBSQgAREGAIIYcpNAdm1cGN4QgMg2QBBpEGEN+SrbONmTWz//lUmRYRJIDv72d6SYBH/wOdanXkEP4wBoVHkURVrI4grwna20FWcNTl5W5LktiVm5a1vfUsG4A73u8WDwCWjS164BcyL1cWKAc7q2e26lwQoSCt458u58ZbXajaoaQNK1rLnrGZ4RjpNlHK4nPRqRQdDIMJ7F/zZ0I6WvmtV6H2thp0OTVVTEpiB5fwAp/NskZbUNXBMNDyRGYwiCAxO8WcXkYEHQ7iYEp6w0BzAp9ocqj3+ZY1peJQxEm4xAw8VsU50oAQxPuQDDlhEOlTM5O5m4MXg1auMhVYbMpEHSqtpDmoaEDNahSmTtESvkGXyGSXwZiEKGEJ7mczm+LoM/8prVc2UhebWDGUYjm0ST4ieYIA0sYdSfpAmJhFg2zHT5As2gGpCnoAMFLP50b0lwijUCmdDxnbO04kOtabTmRoZzcxfSNNz2iPUgBnV0C8ZgCkNkuY1Q/rVQciEcCtdw0tjWkCuaRBu8GwAaaYpAzbwQwT94L2FWlPMqGYJg46tmUa/+tncZfGsaR1C+2J6PIiyQW6ekMXVrGo1IboSdGmV7JmYtcgzSDC0191bFDQBAdSuYbGvTW+rEbrcZA6So9nNb0lTOt4EjHG9B040G5wZ3ysxgAOCQIRe9ELBDLaGNrTxjM8+Y+Lc+Kw1rLHuWLsY4K4TOMFHDjSDI1wlH//4x5qDUI5cuLq3I+jnMbRBAmv4YQQxOAYJuOGHiq+7u8EFOQGlTPKio8zkJy/JE4ZAhu12txyL2O4z/KDz3mrDDyS4Oglwzu/PomAR8BY69+Rs9LIf/eBJ98gXmtD096IA4r09BtX7WfGrc2MERwBHz0dwjBFknN3+Fvv2bG32siM97RwZQBOeLfeJ+yEGJADHEWJwhBHwHe/PqHzXSRCEUXxc8LErvOinc3jEX0Tx0JY7xwXS243r/RnH0HnsN08CoE9b8ISz9ugLr2jTVwT10J76zKm+3dlzPQYjoL3X34371s1792bHqu8lsnZ+453qf7e4H8BR8xg8nuPKb7D/fJtPOJFDv/CvnL5DnmCB8Lv/2UEQLfkHx4qgnn/3RlZ/Qj4Q9ff7H9LSNn9Ed39mZ2b6dxAGwANL9n8M2GTv1j7N52MEWHjSd4ADcQJt14AamGLx9W9CR3gTWHR/ZIH88HIbeILuFX8O8FIg120hWHgGqH5fAHcoWIPvtQiyhnu694JlhwDIlmy2sgV4YINE6F5k0ATaI3iCxoNm9ysI9wFCEAABYAYccAJzsIBFSIRuJnQQYH5MaHQZEGJHJVBSWIYB8AYucAJbUApZSIShtYIgN4BfaHROCBhfgFEHcRtiuBMDYAZm+IdvYAZCIIRtWIMeF4f2N4dmF4aCoRrA/yZRAnFjKgUR1/USTxCFf5iJUvgGQmCFWFiI/+dktwdlEqiIdAgYrCIQWxIz4vEa/xEgJcIfmXGHfoMdaKRGccIzD2IruAElEKAZhtIfAgFH/kERAvUGmpiMm+gCrECIoPh/WxhvIGiKA5cBP0gXWyI5OLIcQQIaM1IjHwA56cEnZRIkllJKuHFjh1Ie1aIEiXYkogQktYFKFwYRM+CHypiPUiiIVviM/veG8eaC1Fh0MbgXg2JRpDaMZgImrmIkd5hhBqFRkegkbLKO1NEhv4gj0YEeFeEMmKiPIHmGabiG/hh+h0hrOziQI7cge6EjApMhvyiJsZJKEsUorjFPw/+CUupIkdVhka/BJkNSiX9yagShAPgYkkgZAC7AAVswByW5eaJYaV6okgSnbXoBOWamannjHnXDLJiBHnqySZNIVVG1JSsYJORRkTwZaFC1JXaCUkXpI8xDPgcBhUl5l2XIj1f4lOzmbmH3Yl24hFQ5cuhzF4S1IrmBN6rjlX4AKEB0kzyEWL20Ij6Slj25ltzmIbxRiZrBSHKpTBajAMiIl6Qpks1oDnwJbQAJZXI4mAM3gtPjOxDwmQPwkaV5m2bACv2YmpB2khDWmq5Jb4zoQLIpHu1AC5OwCZkIAPfQnPcAAFJ4D8UQCfgIANBJmmiohmzImyoWlRA2jcE5Z0r/wEO8cwRCsAmTQAvtIAHHaYbFQBDFEAAA4AdMgA1pEADfcASRcJubmJvOyJ0L5m5JSF/gGZ5TVpjT8wUuYIboOQmjGQDvyQTNCZ3vCaF+EAAm8AH8mYl6+YkAGmnjN18paaDXRiL/0wYg+Z7OwAzF8A0BEAl+YAYmYADzeQ9MwAxM4KIbWoZo2IxD+KG+FX+ft0QjSqJzJi/TIwi2mYyRYALFgA1+YALyeQQ+cAQmwARPYAJHcA9WuqOZGIi66ZRAWnvANYqGNJVGeqTXSC9fcJQgeQ+eUYbPWaPMwAwBwAxP4KXKmJ0k+aEC+l2BmaYjpwR7KC4DEJJpwARP6gfx/2mGzHCfTGAJAYANTKCn+tij/8mbqxlniSio10aokwMBIVkMxdWlZgin0AkAtYEN12mpINmh3Nl5HrhEZOep9YZ2AyMIC+qqvFqaPToHP/qU3plPBWqr0YWr9PIEbtqrzHqXubmbJXmEA1pMxWqss4Ws58IID9qs3OqsndinzxiNxVSk1kpe2Fouh9qt6oqdzJipbbipS/R85Xpf5zou97Cu+FqasFqIODik3IOm83qsA3ML+Vqw7KqGqJmF0mqm8tOFnRqw9EovR0CwBluxeNmuYqqFQ/CXIgScEHut7fIEymmxJOusaTgH21mD8EpBpfix0AWq5jIDI1uyNIuUmP8arCcYBPlDQ9XqstQEs+MCBWvAAtJwBt5Qs0gbkvuqgQsbQrDjs+XVB31QD+YCBI2AAViLAY1QBNMgDUV7tEkbtjw6kgnbgOI6QeQKtSYktUuwBBWABkkQt0kgAuVSBFl7t3irtVwrDddgtGJbs2DalBpIBDYwq9sjr2p7P2zrtnArt47ruAlALrqQt5RbuVt7CHzrt39rsHqZsu+ns/5aOACbuKHTB5ywBBRAAbDwuKzbukngCi8gLrYwuZVbu7art5jbt2C7udx6s/43rP/6sKSbOKaLuhWwunGLvK67vI7bA1AQLlVAu7c7vdN7uZm7u7yrp4HYiXsZfgLKgsT/47HDGzStULwUUAGPq7zMu76s2wPh8gfSm7eVYAcP8ABAkLVAUL+VgLVAcL/Um7fWq7vZu6NmQLbht7IjNL5DU76ne77s+8AQ/Lh0+y3NEL94+wAEcb9A4AdRwA7rgAGVIAh28L//G8BnsK0DHJKYmrFdB7o2pMDTUb5tWwHoG8E2fMNyqwIUHAa1CwT7GwV+8AAYgMFD7AcYEAUtQMJKnLdFUASYewYnnMKvyr2eC23dlYPbI5AQK8OMi8Ne/MVxGw3P2y1hwMO2+wAtwA77i8GVEAUGUAl+YAdRUAJRsL9LfMd428RPHMVSDIjtWrbQ9qfbk7bBubhvC8aInMhJ/+C+3EIKZXy7JcAO7HC/lXAEaRwFcxwFRwAEBhAFePzJtqvHRcvHKby9nrhuRJALhks4gkmVhty4ihzLijzB2mILZXy1trvBJYC/PuwHQFACuwzMoDzM/yvKUIzCSfsGnKid0CakxDO6E/jKsjzN1By3kastVVDGFpy16xAFaMzBeFsCH9zBGMAOnkzM6LzExnwGYrvCr+ZkDwZUPGi+x1vN9nzPjJwtf1DGZpy3D1BcHGzH/OsH+wsELeAHk5zOCj3MTey1UFyznftoAjqK4ltvDIy6quu46nvPHC3LtHwtzcDPCz3SJI3ODT3KFVvAp8lmocWxhkNyF+3AcrvRHf9d0/Z8zdeiBvy8zSXd0z6txCf90OqKhoPYvQwmq50zZzFdwzbd1E7dvNnCz2HA0z9d1VZdzEXg0OzMrAVshVUcbZkAQoS8RVx8yE991mgtt9Hw0ZfSAlK9Al2Ay1c913QN1FmN0tqLsQGKhLM21ghU1rCc1oI92K4wxsBiy/z8Djmw2Iy92BpABJAd2URQA5Rd2V1w2ZjdBXW92SW9tV37tRsa0dslrtCsPNI82Kid2o7L1kmyz4nd2LAd27I927Et2ZFd2bid2ZjN2bwNwHsL2ibbAFsAyKBVuPTXyrNz2qq93Mwdtz4QLGsg1R5A29Rd3dZ93bRt25CN25at25r/3dvp7NkOjb3K6AJFjYX9ujbCS7yn28XN/d7wnQQEECwhXcbz4AEagN36vd/83d/Vrd2Tzd014N3fDd5ZK97AzaHfyoZHmAHCtN5XY74ZHd8UXuHPfSnywM/44AGK7d8e/uEgHuLW/djaLeADrttyrdAIrrmm2ZQt3bNLrbw0XeE0ztzzfSlSveHTLeI83uM+/uP6TeKSbeIEbrsmzAGdyAPviDJLXeNO/uSPe+FIgthlvAgewOFAnuVavuVc3t8Azt3+4A+qcApNDuVmfuZxe+NbgSo6sEERATYTEWrk+RA/INVWjuVdnud6vud8zthGwAPIMAWigADBIAxofuhn/17YW7FY4jHnCHFjEgEBwWYRrl3GV37l+d3nmr7pnL7ffy4JBRDq9RABEUAIl7ACw1DoiM7cPdADj9vq1BDGBCACrv66PRAN773WWnEeMFs3lPUcDoBrrzEDoQElDkAmd8iLkmNW+JEZa3QqTGMf+OHoB3EA/Hzfl97hnb7t3K7pGmAEyADqoT7u50DqEbANV3AJoLACqK7qq57WPTDfKtC8sSsCcasCPkC3ri4CPhDf+XwVMGkQK5gsl4FKhIYeyVKO4CiORIYa7hEknHEgrNIidagQ9R0G2H7p3b7xHA/kGgDo4j7uIi8H5h4BKXAFVwAN687u7W7o7+7UOuwH8/8ut5ELBfaeBH5g7zZPDVBQ6/CN01YRRrpkJq5BNdIiWX6wJTamYwuJIg1JH+JUEFiCZwORaxHzMIGQ9YGACt1w6Xje8WAf9tf958iQCCJ/9qE+BaFQ8hGACCiP8prA8iyf6i7/8h3tvjM/ty9Atzdv89HgB7OuAgSgAirg88ut5laBI2lSKigijgOgGmsSJzvpKNdhGkUiI1J1EAH2i11y9YwCAVq/9V3v9WJf+qa/2GSP9qqf9hfA9qT+9nAv93JP93aPzzIft9TgBz0gAjYft7yfAD2v+zlPt67Q3LmfFT6SHz6yJrRCH1QSRjNAJl7ZIRkQlokl9aqSig5B5WH/cOder+2nH/6b/u08EPKrr/qC7vqvD/tXYAGyL/u0X/uyjPe+XxA3Tw23LgIJ4L6tDhB+eiQhWNDgQYQJFS48mMDPQ4gRJU6kWNHiRYwZMRrgoESCEgcf/HD4mEHCly8SdDw0gECCDRsS/Og4ObPmDJMSMnxwOXFGTAkODGh8WCXM0TAelC5VmsPpU6hRpU5dZsyqsWVOjalT58bpsqxTxY4lW9bsWbRpp2owgkxSAbhx5c6lW09UBLx58xK60tfvpRWBBQ8OPCyYMIaJFS9m3Nhxkh4E/CToEY1ajx4i/IigZrCHH2rU/BCQ3PnxacaSia5m3dr1a9ixW/9BmpTp/9J3assmi5gsxzI/I/hQyuHmyAbdyZUvZy5WAw9kiehOpx63nl7seLP45X4JFGHwhQ+jJl/efEIVEQcS1CzioAoR0ZKIgALF/Xn8BT/L5t/f/38AL2oGqXluY0qD5qCqyhjeRshBHT8ejFCdGBK08EIMnTICOumq83A6ObLLLgXuuIPmu/DCG0YRxPJz8UUYY3wRigBrtPFGHClSg0ADmcqwuIe8UucIN4Z0ww9jRkhmBK9+dPJJqDZ860Mq6ZoiFBGzQ6REEzVJ8csVW5RxTDLLJDO9HNNUc03XasOnR9wyHCE4p4zj4wh1hBvSGDyh9NNCtniYskpC5ZrigixF5P+yRC+/BJNFMyOVdNLGNGPzUkwz9YOU2haBcykMj/SjSa2WOZJB35Lx7U9W02LLrUJjnWuKuxLNbo9FubPAUV7DpPRXYCfdT1Niiw3Qlk4/VSo3CxucKhniRrAkB0scbPXaqTaMTlZu5bLLVhH5ytWvXXntFdJg01UXP1dYM2AAHRQQKSMEIMjoCwS+MHZf1mhDStmlEGzOGD+IlIpgr5bhww9LwsL2Wm3h6rDbbq8DV8Ttxv3LXI59XfdjkBdb7QmPJDBZIwkQyAgCG/h1WaM1agMY1IdrblVKinOeK8SLRdxSY79O5LhjdEM2+mg0M4pJAT8+sBfeD+T1QwEEHJj/4aGUqeZgKHhncMCBJ/zIYKWpEah33pfTHvCoAmduyma4L3x1UJ3rnoLnnrMzBGgTURzaXI+PFjzdpC96QieJXPLoCwgkgMABCa42OYOYOPDDJRtMavmLoUiCQIcM9E077Wl4dNsDZuNW3VXo6K779QIQzTtLaPjmrtG/iYZlcN4ntRSjlFSOyKWh/FAiAz8MCMqPlJNvviexZYIIcgd0EH30l908XSmBV/deKm0nhn18WmdPVFzb+yo396EHoWP33uOP8feLPvioeJGgZ1745pvf/3Lp6S95HMjJ1bDnsmRtzwPd+57qIjY+CHqrVuYLV/p0xT72uQ9+8uNgeeh3/xGS2EAHHQHg9CJHE6b573kBlN5DOKAAxkmAaQfkVwK3l7oGPgxnEeShdShoq4xZsC+AwWAG39dBJDqGPhoxAAQ8ogTL6c8AkFOCvf73P+gJUAdPtCIN9yUzBS4rh6x6lfh62MNz/NBWPxPiEP1WxL9pMIlzXMgHvXhHTYExjKgb44+es60zBhIud1OjrS7Qxr7BsYhypGPIKLAESEZSkpP8hA4seclLXg+Pm6yR6fa4wD42J3yCJGVcZFfIRN0BkbdTJBwZ2ch0TVKWk6wHJm2pSU7msj9IedMnuRdKtTywlMMsHypthb5VXgF3rcTgK2HZOzvqUpoB4qUvAwbMsf8EynXDLOW3jGmrbSTzgsxUpDOfabRoTsQAKPlC2B7yBAQMYJrznMiOwuApa/4Sm06ZGzf96a1vXoxE4twYOVvpvnMiTSMpMdlLwvYB69FTog9ZGz7zCco+/tGM//RnGgMKLjYS9AreMWgrqRAMOiT0Y4WzSPD88AUlKMEAENVXE822EgPooGoGhIDZOOBOqp3NDwMw2wwniiN/XdRH3xMmR50KF7x9NFGiEGkiS2pSlKo0WERx6UhkmJKV2EAJOmCZ2MZqkrCJ0Ikt8xzoYvg4GR4VR0Zpm1L1WbMdPlWvcDmlVG2lyqr2BRrLvCocT5pSrUaqXQv1H02spxLjQVH/Bx84HAJGCFnGIcAjfqBeRJUgQpoIT6414lRd7YrRP/Vzr6stwKH82jNkBpawhTVsVhM7pmEBz38kGQBY/fAEB8RECQNIWSZnEBScyIQjBXzJJeU5WhtNo5envWuG/rhN1j61mK8FVxADqz7alvSwt4WRau6lky/QBHm+jSe+JECy4X5BAfBSyU9k8sIYKgBy1oMXdG10gOlS1wMYGmUBNppdp1qMuwL9boks8MbwYhWx5DWPFrjaUCgOxbeQe4k8gWsyG8zAAJqLyUy4OMAnks2/APqBRQWMWt1E7MAI3qtHF3yxkDZ4pBEu7HgpjBqWrljIFXnxbRhYlrzSWMlQ/73x7ACrY8FCmMfM9PGPF4MGhwxZy0Qu8oGy2ZYZLxnBfW0yuHAF5aBJecpUHo+VGVKBLcd5IkboMlNweF0x59lQZC7zMdHMqDWH1zBicrNBCiFnRD9kA3W2M4f0/Oi4bLfPF/Pun6GxvkAXdtCFJggsDp1oOXeC0UuJBRsgfWoFT7pnOf7zFTCdaU23+ccVsDCo5UznUY9iAuI4tZ5TrWoct5pLRIR1hDdNXgrU2tZbXvSoMzGBCYQAwVYQgxhwERdciMEU4YCLFazA2qgCu2e8EHaJSFpsHh87oWigQJCX7V9ROxva0WZtP/zgDGf4QQwFsIIfuOCMLxQgHFDox/9eryRuCsa23EJD95TV3UgKUKB479Yyrg3UDbvOe96m1qsy/IADXPhBGQUQgx9IbnI9PMLgWEK4+RS+8Nk2nLYP7yC7KUDxOJPDQI4oRy4yrnFoc9yp9oaCMqDwbVP4IRx6MEC/ccAFZXCB2/6UdMt7Vuly+yXmMp+5rOUX8U/jfMhHuMRSutGLnts1FkCfN6+digsoPOIhBbeCAR5hAD3oQRlMxwXe/elNq8+O1VkHL9czHbjB2fwcYme2B84uAZ+fVtdsn7dTh8Lvh2Db237AhTJG7nlu/jrwPbtA7Qg/bMMXG/GOjLiyGb/iVeQC8i+ePOWD/s98myLpzphL1Av/8O8COIMLwwz36PNG7tOjPvWqL9q6bE4BE7xeyApQQi4w/uJn277t/rSC3P0gi29j2w/f7v69wx9IQhr/hy9PPsOXD+vVUwoWEY+4u6U/z5+EzhJdzr72oS3tXuuhg1O/Hwqn5FuUwXq/hos/M6kA+ru5+zsqfLGB5/KDZhMw/2M7oQvA16k6AsybgTrARdk6BXS45iOT56MAOohAifqAjtCBiWOYsqOutctAoANADtQZwPtA8xk8ESy8ElzAE3wRWHBA+gs7FsylnMowivACAatBGwS6DczBWBE9HswbUXiyH3SwIDQ8BjQPI6Q/TEhCXRoAJUAAd6IIsqOu2otC/43DQSokFBu7wh/Swi3sji5MvRXZIPNgtzBMNjLkpODCJYrQOclzQ9ubwjicjvSjQzVivzt0vzyUOXNyjBSkP/sLxLRBm4wog9PqP0S8wUWsjgF0RDUywDtEQDWLMDX4gzVQA8FoBlfMhsBQg2ZIvUpMjCL8w4hjBk1cMUuYwYsKRf9zu1GMND4zxdkJwVQcwUw7gE05AkGARTXwgyoghR9YgWw4ggNQwFxMCF6kv18UMin4OWK0vRBQxBzcQWWkIEQwvWZclFcLryPwg2yAxipYgT/wA33kxypogTz8RoKoAAfkxRUcx4lgJ0IMkJ6SiIZ0DU/MJyg8R9szRiq0wv92NB/ki0d5XLOHyIZm8ANbWIE1sMcqOIJs8IMDqAJbqAJaDMJKRINwBDuEnIiG+ogKrJH+Gp4WYo1glEiKzMB0pMI5zEg1AgOOHBdiC68q2JQWEMkVUAMDaAEDqAKWPMlmOIJ8nERGsrmCfEBArMmIOJkPMAnRISoEmCGvQQAO0BcdgJd4Ai6heAiqsZqH2MkZqJoSew1D9KU2DEp0VEcxKz6jpCBASEqlXEVmusc/2Mc/iEU1qMZmsIWRpMxJHIxBkEkjDEfXE8uTGarlaRy4mq+g0IHqYR6d8IjMkQDLEU3IuZqeOK6x2cvXuMA9+kvArEjBzK5SLMxCwjrETLP/8GqGZjiAIzgCWBwMW8jGKmCHFSCFrbzMFUgFCiDI6rzOB5QFsRxL6XGpz7KkrNGJt8QalaEJfWme43EeByghyMmfnmyNI7C4MALF3NS+EIBDGnMt3zSmeAjOcUnAwtpHP/iB5IxFP6DGpySFAp1EAUgFgpzJiPOB7YSIzyQuy2kuS5InnTIZe2ke8/wfFVKZnsii92yNThBGBarPULRI1poC42OAcRiHasgLGJVRvGAABggoQ4BH/+QSEpTOYtuBHfAE6/xKsJxQCj0JM1QCkdivL4AXBYCAJ10eD62J5nlNFCohx7Iv/qCET1JRYmTRp8JIVRsHP6gPKJhRBvCD/wV4gQTACygYh4/ayB7lknkE0iAVUiLdTLCkACTczpsEG5boiI/QAfsKiqGo0vNUmSn6CCvqiZZ4CdqMjXJUoIkEUzcU045SPxqJADNdAE/1g1CNgDaVKqSs01xZSjyFNSEV0iUoUuykv8VDUiGzzZm5VEzNVKciTIR7iGpYUx8I1WpYgDT1AwZYAB9YgBlFJUhEVVVd1Slr1R0QgOq0zj4NS1pdsYh0G9zMVV0lJpZTvwXwgxd4AT8I1mqAgheAggVAVmJlAHY1JuBEVeGE1miV1h140OvkxejL1hWLz9OhT2+NwvsMAU2FIP38wBg1Uzm9UQaoBmP1gWCVWGPywf9kKgMp8IIO8IsO8AIvOLMyKAOCAlB7Lax5wNcdcFBrDcdM9Fd6OoJtVRaBHVihLFiD3c2c8cDRw9FxqI9lzQsfeNNSfQFQRaULoFOC2gCGsQQ/8IIrKAM/gAFLoIQr2IPjqKofLVn2OVmUnQBYvdYYdNnRWgUUhROaJUabtVmclRV2VD8znYwc1Ys1VVNzfYG4RaVZ+K448IMO6AA/iIMr8AI/CNzBlQI++K471Vr2EQCU1VN9jVVxFFshO1Fl6YazDcW0Tdu1rRIy3U+pOszAUtojiAOYJdw9kAKY5VsYiAMYODNxSlzF5ZjGbVVF2NdrnVXJXTHKhRNcvVz7zFz/m50ANthc6uBVz/UrVBSpDjiChbHAqmXeI5CC1UXd5ZWCqnrW2OUVrp3dHXjVMOTFMczdyS3bpehW36U84AVecSDeSAvX422yb/iuenzah+DYMtgDvo0DwNXfwJLE7P0SxuVeIdXXmexM8R2t3b0N8z3fG0zf9D1YukjG932tdwwspvVYhimROKBaqb0CS4CB7/Lf/x2M7RXgfH1cXmzZA6anBF6KmWXgBnbgB95NnZ3g1xIFpL3Y5qUEkeVYPyiDOyiDhbGEHv6urNXaADbhlCVgsF3hIbME+fQAGK5ZGa5iMW1bG16wvKVXIbq0ERaMElbifUBhsPxTJ4YumGWK/yn2vypu4/tcX7jo3Cz2K9DlYiGC3VWlAgFIYiUe0q/9w/A9YyFLYw/o3TX+Pzd24wmQ4zmWquS14/TB3lU9WcblYwEWAO+lvxQW5MYz5ENO5ET+BCdAAglu5I9iRkiOZMXMQ0qe1j6WVjr42gc8SE7WMi9Y4DUGZTf2BSfoZUhAggkyZalCBDtMZb4RYVZ25Uq2ZBN+XMgN5FoeMn44ZHTU5SrOh17OZicAAUMIZmE2Jiww5jYiWVbeY2V25VdO2WqF3PqL5jjDAWpmO2uuYm2u522Gg2/+plMVZyE6YnSbB3OuZGVmZu5VWT49QneWM1OI53mbZxmuA3uOaCQwhP98VqM65mcLwuNiA+hzFmiBfuU9xc4wNOCEXrEZYAOGdmgHhuiIrucbeOmJ9uaKTpR5xWiNkeRMowKADuiOPmeQJuOIowMaKek4ewR3iGeVTl9RbmltfmmnvgFulumZ1ot44FGbth2c5rGd3mOu7umPfuVMBl+iRrSmo+akBt5NYOqmfuqnBgE4kOqZNoQcvmqgQWba0mmuzmue9mh07mNqtdZYldCxRrR+OMdTCAGKPOvM5WW17mW2fuwbgAQ4oOipzotfoOtx9mc42mq97mq+/upXhtUwhObBjrOTRsRd2IWgVOy0bexshmzYvgEkeOup3mfMtiDN/hs97mze9ur/aSXo2TVo26WAoS5tRHuEM4jCUyiH1WbtghUH13bs2IZtSHDrC4Dr973o204fjR6aeeBs3tZr3wbu2fVazjRuWzMAeM5ACTiF5nbuEGBp155u6oYE+4YEGYCDUvbN+N3uNuruL9nt8B7w8e5rJQ7przRj9JYzPUBp20ttwITv+/wEbG5s+q7v+87w/N5vZSRm/26jrAYPvB5wEvds307nPTVSFV5wIXOG5Ga7U5CA3JTwEFhqC7/wx85wHc9w68buKzzaDx/nVV6BES9xIy9w8kbZTI64CsBdFl+2hQa69p5xCWfsG8fxp95xLdfwyRYFHze+PAhyIRfx7zZyMzfx/89O5wGGVWEo7idfNlk4amiDcCqHbytXayzP8i3fcxDo8z6f7W6mQ+0Wc765Ay/Rac4GaPA+884e7yRHWSZmgjcXOwMo7BhXURqPbifIc6fecz73c1D/8y7/8jLbBqsmdC6BhjvghVmYhSZQdAGA9Vhn9BIv8HQWbgog7Ul/Ny6Y8jp3buiObk5/aU/f8lA/dlCXgYm+boTrb1QvEVVn9VafdnzQ651edFoX7zQ351ce44JU8F23ta8p7F9nbfm+8jwvdi1Hdnbvcxl4d2WfbGZvMkSY6+2O9mnP93yfVlm/9mwn8G1X85AWhnwLd5ybAZn6vhdPbAm3cTwf9shWd/8eb/d2h3eLh3c4kHcv/yhR2OLbVvVV13eRz/c82GNY9/d/7+2Af3RpVQTrXHGDHzIDUAIDeghTcHDMpfFPuIH5hniJn3iKP/aLH3qin239vm5Szw5iwOg7aHpekPaRj/p8j4VEn3WrT/m8tvV09t5+jfl3cwDLkYgPwIVzpPE7Z2qf//n7DnpkJ3q3v3gkiHu5N3p57+aNz45BT0poAPmnl3q/9/tYMPmrH3ys3+uOZnlpJUhd93pEGwAbCFuIiPOch+9aEPZhV/u1Z/tQf3vOV/a5/3zQn/uMh4NvePqnb3pV33sou4O9Z/2mX3XTx4K/n33ad3V/7/fCz/qAv/X/Clh8xo+zD1CChYyIm3fDTLd8Tsd8+9b8ze98tw996If+FMgD6qf+X7h+7M/+6592ae/+Vpd27cf+2h9/8s/3ar96lM99w/doxBfSVCgEN/99RKsXjTiC9WZjCT/3h09+5QcIEAIHEiw4UAbChAoXLkTi8CHEiBIdbstj0eKvjBo3cuzosSOWWSJHkixp8iTKlCTxCZjX8qVLATJn0qxp0+YOATl36tS54yfQoEJxQfFj9CjSpEqXMm3q9CnUqFKnUq1q9SrWqQpsGJjqzMqEsGLHhihr9izatGrrOGnr9u3bG3Ln0q07FxLevHr35jXotyDDwIEnEp4IqeJFYh8X/zP2GFIl5MiSReacGVPm5Zuab/Ls3FMoaKAHspIubfo06tSqV/v5oOSLVVlgx4pVa/v22U9wd7e169su3+B6/xIHIfi4wsLKIQK6mEdx4+iMH0+ubn1WHpiYX3Lf7J2m586hQY9mbf48+vTqzSOAkJWLO9oTcNNXu4n37t/65QrvX/wvcsgtNyASYDgnHYIfUXcdgyrF4lJMEG73HYUyhffZeEGVtx6HHXr4oXpbdUWaHvHVVh+KZfmCH1z7/daff/8ZFOBxBCoHh3N5JLjjRg36qFITEdKUWYXeXbhThqKBuCSTTToJlWuwnVZiWCmmmA+LcbkIHIzByTgjjYPZSP9YPDnyeOaPaZbESxM1SUhkkZx9NqdPGQ7wJJ556tlhe6uVaGV94mSp5ZZ0denllwSFKeaYEn1j5pk7qjmpSCxJ2B2ccYI3p3gZVrEnqKGKSpoCGYy42gxWAHobW4P2Vqihh+6VqKKLNtSoRFk4B12k0i1IqY+VCXmpppodaWFo6NgyKrPNOqvUE0o8kZ5sq6b1CZaDwlqXrMPRepCtyeEK0WG79orgr8AymBOx3RUr55GhqbHKs/XaG2oGOnD4CA7WmqWbq9vG2i0k3woU7q3jPtTcReeiq+6Psdj05rs1AcUpp0IdcOq9HXsM4gcfOmMKG9beF7DA/BFcsMEIJ6T/cEQGNuxwdBBHrF27FdNUTiDHgvbHx0ELPXRUR/yZojgroizwyngZbJzLMsD8kAyQ0syYzT62qd12mRYbSDk+A6Us0WWbfbYfsvSLoquvMt3001FLPTUSZR54NdZZMxjkkFzrvPPF4f10gCBoG364xyO7g5ugbad8Q9Msfys33Ug8ejfeH+nNID4Ue/03KuVgvBM6QCN+OurPcoGLba0uvW3kcUddOWIW8Zo5R+luDhm7mLr7t04SBP5ZMyGnfjzyoSqOFsDaPg637C5XzrDtuDu2e3XZ9Z3z3zmF7hk6nyY/Pvl5rv6v48+vHL30U8tAvY7Wg4T9ZBJfetnn7+4g/zxPBxxRPgADyKQjiOEMSnNeyqA3udnRDQ7EwJz8NEK/+k2IYsDbFCpQ8ZNmLEuAHnTSE75gvA98YVpQ6dMAEPCEJyDgTqBigj1eB6vYtYyBU7PbzCIowQlGhm/u4l7FKrO/V4jvg0ZcEgIk4ACj2EACCGDKFySgLz/o4E46kIAIdQCbK0opTz6IRDxYpD6CAYN94apcCqymw1/wMDKd4w4Qu6cTdPyDA0e8I4iSKIEPzEACTjTKDByAAAUYhQNO1FcVqYjFD2jxA0nkwABmoIOQDUAHHAMRE2jAmzHKChjtMKOtKne5HOpQd21cSddwdkELlc4AH9gjHmO5niTaAP8CDmjiE/voAAhIwD0ZkIANnvhHLkZRB09oYgYgMAAJEFIJNsgTFJigD0LBjmCToAUoF0U3ENTuOWvMiClPSZnfTeiCrTwKB9wjy3Wyh5lKYOYfHSCBrmRACX4oplGGiUV8ctEPBlBCBvpIyD1hQ5pO4OShaDGJGtoQZvC7XQTDeUrtqTJ/RTonUlxzSXZylDRJNIAEMhDFJybRKCXFpx/0+QV+YrGQIZ3nqAqqj7fJSgbtKOMC2+c++H0TnOJEyYMqSs4izYOITXHAFDuq1KyU9Akk/KMCpKjLeypxBil9IjGlqEgtUlWJz5LplpomgRswFGGVwxEEdfhTlPDNopr/OkAHm/IFJWx0qXY9oQSOMlKjQOCdDhhREu2pUnx+oIlL9EMTrWqvaNJAPyvbxCfLeka64RAjPV2rSdi0Pb9RqKh/IIVUEJDUu5IWTyB95segwAwwcsuatJBcoihHt1Fa9puYNQlL4MjZ7xzgB1WZa2mD+6SojjZoPjDBTCFHMIVmM0yV01VieirRU/ZuqJvZgRqqUNeotFC43v3uUqIZCXt066bNpRHdZNBNiMrvV47AbO88t5lXfLY0M0AtePOrXx9ksksSOC966cZT6ZZEAmuV2MTIid01tCA1NnChfiOcX2aYoLF7gSyABURZmdV2jb8y8E/tx9nLZNd4qhkA/34lrGLwUpgGeLlmhmtUOTWqtcBr3VoFW4KOA2g3PSZeMZDB6wME0CMUkg0lZWkcQZOAWJxt3U4z/kCvIFO5yqqxAWywsYBi0OBLsp0abeNnW5JgoRfvFecbBaCGNfxgu1Z+M5ylAtKl8LfCAGqowrbxwOp9M11mFmcZDsBmN8e50IaG4hOfUmca2ONgeMZVuaLbZ5P8mX5l8EIcDq3pTUtFB+qcimqZUGF7TBZmMuCwmD1M6TPbbA8dkEKmOS3rWTPFARDGSqgrrA8ZT82BaV3yqoHlakz/71khXOlKTUjrZZ/NBspODTaYIWoaMHpudNtzh2tckkozaA+XhkesPf+mRz/+kdnmHtorPeQDZizABBWmQSjGlMZfy+8k3E4JMcpQhg1guhNnC6EhOVDCLxhzACLkAALa05VKGoXhjJwBwp8wgz75IYUIcIBiz63x1ExcT8xYt7vfTQN9PCTMPWWjSXKRC5LouwNe8AIl4lDs1F1xild8pxZFG3A/lJTneY2iEyXgzCbeaZc6aOKPN650rHi6Y4x4uRc2oO+pW48Y0Jj6vqHOAVbEwRJGrLlRrpjxASD8jz0/qVbRri9GIqCJXVw63KuCgIyjzhJxuDve8353f09FB8UVINgVKSVeQmCvZ/952hE/SYCSvaVxf/xUlJD00vr9joHvp89nsMz/J8pzl++kqr7UHkUHfCGJb4c86pfimvxW/oiXd3y0gv7EYyrxl6D3+e0NCVDHp773Sek4eFvv++EvGwJ/L60C7Ej85ct67vktPfOjr2lYghf60r8+nCcfXOtjv/veRxv3vy/+8Xcs/OQ/P/pDZf70s7/9S1q9++Mv/w7ldf72v/9q6o///fP/KoTuPwAyiSTpgGJRXAAeIP8ZwC8hwC/pS7lNRc9ZRQQiIAXK2hWpk8RdlQIgAAd0hQFAAAeaUBU9gRY1EVcdhQEgnN9tkQtV0ReY4OlVoAzC2TIdkgn5UQY0kR3Vkw7UU8gInR8NwDt111H8EgQYkgMmmhMJ4RLO/6ATFpoOvFMQXpU/OdET9JIfCFRKZcBRTCBV2RE+lZvZ6d8TliGVjcgT8JIwKSEC4FMYJhruIYUbapUYkhQZmiEeSpgOtNAXICEVUqEzfYE8TcsDJtEMKNtpfQEv6cs7HeEYHmIeRqJ+lZ4f2cAU1aEfPMEvPVg+weEMvNNANdwQapUQKoEaZiEoSqIqxp3BCaIE0N0qxmLqGRIwHZ/ZkJCyhdBGsdCtOQUvyiIwBtkV4pcN2JNSoBRUIGMwLqN+JdYXZiLCQUBXFJMBJNLDMRJsYCM+MVzF6csHJpwtMqMsptCzeVBU2ZEhORVARSEX4lMx+kFUGZxWFRM+HR5iKf+Bp6WYOMZiz2GeEYEUXQEUPL6iH/BSCGmV2DkAXc2hFiWeSeWVEigBB0zSPkriBmLcPcHgFSWf87UGwnHAtFTSByiA9pmNPCURIfVTVq2dBOwcQ9Zj/TXVLQldSVYkBRKePGneEFaS0OnRB7hGvkSkz71TDJ5NH/lRV1wh6b0jSv1SS10hPiZRQ+pL5/VVXvFhEpWjTcqgQILUEvVjS/HSF5zjHmLRRyGPDh4FioXUtKDUMuEXL9kAEuIT7TmA7ckTMPXiVsogJoLlFmHRFU2k3znSHe6lYS5VTm5k5pFgS3HRFQaUIrJQYR4mZa6TAciTKQISKKpkS82AU2YAYVYbpmiOJmmWpmmeJmqmpmquJmu2pmu+JmziUUAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: the Intestinal Transplant Registry, Final Summary 2003. Reproduced with permission from David Grant, MD. file://www.intestinaltransplant.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_49_29471=[""].join("\n");
var outline_f28_49_29471=null;
